

CITATION REPORT

List of articles citing

Guidelines for the diagnosis and management of gastroesophageal reflux disease

DOI: 10.1038/ajg.2012.444

American Journal of Gastroenterology, 2013, 108, 308-28; quiz 329.

Source: <https://exaly.com/paper-pdf/55798930/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1218	Reply to "the importance of subgrouping refractory NERD patients according to esophageal pH-impedance testing". 2013 , 27, 4403-5		
1217	Functional esophageal disorders: a review of diagnosis and management. 2013 , 7, 453-61		22
1216	Esophageal pathology: a brief guide and atlas. 2013 , 46, 1043-57		1
1215	Selected commentary to Esophageal sphincter device for gastroesophageal reflux disease. 2013 , 45, 113-116		2
1214	Endoscopic treatment of refractory gastroesophageal reflux disease. 2013 , 46, 230-4		7
1213	Management of reflux-related symptoms. 2013 , 27, 387-400		4
1212	What is the role of endoscopy and oesophageal biopsies in the management of GERD?. 2013 , 27, 373-85		24
1211	An old tool may fix a new problem: early utilization of 24-h esophageal pH monitoring may reduce unnecessary proton-pump inhibitor use and improve outcomes. 2013 , 2, 409-11		3
1210	LINX() Reflux Management System in chronic gastroesophageal reflux: a novel effective technology for restoring the natural barrier to reflux. 2013 , 6, 261-8		55
1209	Optimal treatment of laryngopharyngeal reflux disease. 2013 , 4, 287-301		45
1208	Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. 2013 , 48, 1018-26		5
1207	Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn. 2013 , 25, 1450-5		6
1206	Commentary: biopsy to diagnose GERD--better, but not yet a stand-alone test; authors' reply. 2013 , 38, 1140-1		
1205	The efficacy, safety and cost-effectiveness of hydrotalcite versus esomeprazole in on-demand therapy of NERD: A multicenter, randomized, open-label study in China. 2013 , 14, 463-8		4
1204	Commentary: biopsy to diagnose GERD--better, but not yet a stand-alone test. 2013 , 38, 1139-40		1
1203	Stretta for refractory GERD: now more than ever. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1655-67		
1202	Response to Savarino et al. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1658-9	0.7	1

1201	Stretta radiofrequency treatment for GERD: a safe and effective modality. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1654-5	0.7	11
1200	Response to Franciosa et al. and Triadafilopoulos. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1656-7		
1199	Non-erosive reflux disease is more complex than negative endoscopy only. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1657-8	0.7	
1198	Diagnostic indicators of non-cardiovascular chest pain: a systematic review and meta-analysis. 2013 , 11, 239		27
1197	Sleeve gastrectomy and gastroesophageal reflux disease. 2013 , 2013, 741097		58
1196	A Study to Draw a Normative Database of Laryngopharynx pH Profile in Chinese. 2014 , 20, 347-51		14
1195	Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. 2014 , 20, 2412-9		59
1194	Laparoscopic fundoplication for gastroesophageal reflux disease. 2014 , 20, 14272-9		51
1193	Impedance pH Guided Approach to Proton Pump Inhibitor-refractory Non-erosive Reflux Disease. 2014 , 20, 419-20		1
1192	Validation and diagnostic usefulness of gastroesophageal reflux disease questionnaire in a primary care level in Mexico. 2014 , 20, 475-82		30
1191	[Current issues on gastroesophageal reflux disease]. 2014 , 64, 127-32		2
1190	The role of primary care physicians in early diagnosis and treatment of chronic gastrointestinal diseases. 2014 , 7, 159-73		38
1189	Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison. 2014 , 55, 178-83		9
1188	[Clinical improvement of Los Angeles grade D esophagitis with proton pump inhibitor]. 2014 , 63, 134-6		
1187	Effects of aging on the digestive system. 2014 , 45-49		
1186	Test-based exclusion diets in gastro-esophageal reflux disease patients: a randomized controlled pilot trial. 2014 , 20, 17190-5		4
1185	Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease. 2014 , 11, 964-8		36
1184	Efficacy of transoral fundoplication for treatment of chronic gastroesophageal reflux disease incompletely controlled with high-dose proton-pump inhibitors therapy: a randomized, multicenter, open label, crossover study. 2014 , 14, 174		33

1183	Refractory gastroesophageal reflux disease: advances and treatment. 2014 , 8, 657-67	13
1182	The impact of comorbid gastroesophageal reflux disease on endoscopic sinus surgery quality-of-life outcomes. 2014 , 4, 663-9	18
1181	Evidence-based treatment of frequent heartburn: the benefits and limitations of over-the-counter medications. 2014 , 26, 330-9	6
1180	Bolus retention in hiatal hernia identified by high-resolution esophageal manometry with impedance. 2014 , 26, 679-84	3
1179	Association between coffee intake and gastroesophageal reflux disease: a meta-analysis. 2014 , 27, 311-7	34
1178	Gastrointestinal morbidity in obesity. 2014 , 1311, 42-56	25
1177	Correlation between oropharyngeal pH-monitoring and esophageal pH-impedance monitoring in patients with suspected GERD-related extra-esophageal symptoms. 2014 , 26, 1557-64	24
1176	Initial proton pump inhibitor characteristics associated with long-term prescriptions in US veterans diagnosed with gastro-oesophageal reflux disease. 2014 , 5, 157-164	
1175	Transoral incisionless fundoplication for the treatment of gastroesophageal reflux disease. 2014 , 11, 341-50	7
1174	Helicobacter pylori and gastroesophageal reflux disease. 2014 , 30, 402-7	25
1173	Primary care of chronic dyspnea in adults. 2014 , 39, 34-40; quiz 40-1	8
1172	Evaluation and management of gastrointestinal manifestations in scleroderma. 2014 , 26, 621-9	28
1171	Manejo endoscópico de la acalasia: revisión clínica. 2014 , 26, 95-103	1
1170	Does Barrett's esophagus regress after surgery (or proton pump inhibitors)? 2014 , 32, 156-63	13
1169	Medical Complications of Eating Disorders, Substance Use Disorders, and Addictions. 2014 , 323-362	2
1168	Echocardiographic manifestation of esophagitis mimicking a posterior mediastinal mass. 2014 , 8, 23-5	2
1167	Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis. 2014 , 46, 596-602	32
1166	Early referral for esophageal pH monitoring is more cost-effective than prolonged empiric trials of proton-pump inhibitors for suspected gastroesophageal reflux disease. 2014 , 18, 26-33; discussion 33-4	6

1165	Multilayered epithelium at the gastroesophageal junction is a marker of gastroesophageal reflux disease: data from a prospective Central European multicenter study (histoGERD trial). 2014 , 464, 409-17	23
1164	Efficacy of super high dose proton pump inhibitor administration in refractory laryngopharyngeal reflux: a pilot study. 2014 , 28, 369-77	17
1163	New Approaches to Management of PPI-Refractory Gastroesophageal Reflux Disease. 2014 , 12, 18-33	11
1162	Prokinetic agents and laryngopharyngeal reflux disease: Prokinetic agents and laryngopharyngeal reflux disease: a systematic review. 2014 , 124, 2375-9	21
1161	Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium). 2014 , 15, 1215-22	4
1160	EAES recommendations for the management of gastroesophageal reflux disease. 2014 , 28, 1753-73	131
1159	Fundoplication versus medical management of gastroesophageal reflux disease: systematic review and meta-analysis. 2014 , 28, 143-55	50
1158	Medical treatments of GERD: the old and new. 2014 , 43, 121-33	22
1157	Role of endoscopy in GERD. 2014 , 43, 39-46	10
1156	Acid and nonacid reflux monitoring. 2014 , 43, 89-104	6
1155	Condiciones clínicas y terapéuticas que requieren gastroprotección. 2014 , 21, 528-533	
1154	The role of obesity in oesophageal cancer development. 2014 , 7, 247-68	51
1153	Proton pump inhibitors and risk of bone fractures. 2014 , 12, 414-23	35
1152	Accuracy of diagnosing gastroesophageal reflux disease by GerdQ, esophageal impedance monitoring and histology. 2014 , 15, 230-8	20
1151	Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease. 2014 , 10, 1301-11	2
1150	The impact of proton pump inhibitors on the human gastrointestinal microbiome. 2014 , 34, 771-85	90
1149	Acid-based parameters on pH-impedance testing predict symptom improvement with medical management better than impedance parameters. <i>American Journal of Gastroenterology</i> , 2014 , 109, 836-44	52
1148	Management strategies for achalasia. 2014 , 26, 1215-21	17

1147	Endoscopic management of acute peptic ulcer bleeding. 2014 , 43, 677-705	4
1146	Noncompliance is an impact factor in the treatment of gastroesophageal reflux disease. 2014 , 8, 761-5	8
1145	Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. 2014 , 40, 695-704	74
1144	Chronic cough and OSA: an underappreciated relationship. 2014 , 192, 21-5	13
1143	Univariate and multivariate analyses of preoperative factors influencing symptomatic outcomes of transoral fundoplication. 2014 , 28, 2949-58	22
1142	[Chronic chest pain]. 2014 , 28, 282-8	1
1141	Gastroesophageal reflux disease: diagnosis and patient selection. 2014 , 76, 453-60	8
1140	Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. 2014 , 34, 83-93	6
1139	Diagnostic work-up of GERD. 2014 , 24, 655-66	19
1138	Reflux and acid peptic diseases in the elderly. 2014 , 30, 29-41	8
1137	Management of sorafenib-related adverse events: a clinician's perspective. 2014 , 41 Suppl 2, S1-S16	90
1136	Validation study of the Esohisto consensus guidelines for the recognition of microscopic esophagitis (histoGERD Trial). 2014 , 45, 994-1002	35
1135	Pantoprazole increases cell viability and function of primary human osteoblasts in vitro. 2014 , 45, 1156-64	17
1134	In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor- κ B and activator protein-1. 2014 , 63, 1042-52	53
1133	Controversies in Barrett esophagus. 2014 , 89, 973-84	14
1132	Serious and commonly overlooked side effect of prolonged use of PPI. 2014 , 127, e5	18
1131	Gastroesophageal reflux disease and the elderly. 2014 , 43, 147-60	24
1130	Do endoscopic antireflux procedures fit in the current treatment paradigm of gastroesophageal reflux disease?. 2014 , 12, 544-54	33

1129 Dyspepsia. 141-148

1128 Diagnosis and treatment of gastroesophageal reflux disease. **2014**, 5, 105-12

131

1127 Cutting edge of esophageal reflux. **2014**, 41, 665-669

1126 Response. **2014**, 146, e32-3

1125 Unintentional Discontinuation of Chronic Medications for Seniors in Nursing Homes: Evaluation of a National Medication Reconciliation Accreditation Requirement Using a Population-Based Cohort Study. **2015**, 94, e899

2

1124 Editorial: anti-secretory therapy prior to anti-reflux surgery. Does dose matter?. **2015**, 42, 626

0

1123 Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease. **2015**, 30 Suppl 1, 36-40

6

1122 Reflux characteristics of 113 GERD patients with abnormal 24-h multichannel intraluminal impedance-pH tests. **2015**, 16, 805-10

4

1121 Esophageal adenocarcinoma: risk factors. **2015**, 35-44

1120 Helicobacter pylori and esophageal neoplasia. **2015**, 79-86

0

1119 Gastroesophageal Reflux Disease. **2015**, 906-928

2

1118 In the Clinic. Gastroesophageal Reflux Disease. **2015**, 163, ITC1

7

1117 Using omeprazole to treat intestinal failure. **2015**, 13, 14-16

1

1116 Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?. **2015**, 54, 97-105

3

1115 Issue Highlights. **2015**, 13, 1033-1035

1114 Effects of acotiamide on esophageal motor function and gastroesophageal reflux in healthy volunteers. **2015**, 15, 117

10

1113 Idiopathic (primary) achalasia: a review. **2015**, 10, 89

30

1112 Gastrointestinal problems in modern wars: clinical features and possible mechanisms. **2015**, 2, 15

7

1111	Changing Patterns in Reflux Care: 10-Year Comparison of ABEA Members. 2015 , 124, 940-6	21
1110	Deprescribing versus continuation of chronic proton pump inhibitor use in adults. 2015 ,	4
1109	Protective effects of quercetin against chronic mixed reflux esophagitis in rats by inhibiting the nuclear factor- κ B p65 and interleukin-8 signaling pathways. 2015 , 16, 319-26	7
1108	Diagnostic value of dilated intercellular space and histopathologic scores in gastroesophageal reflux disease. 2015 , 28, 530-7	6
1107	Critical Assessment of Endoscopic Techniques for Gastroesophageal Reflux Disease. 2015 , 49, 720-4	14
1106	What are the precautions with proton pump inhibitor use for reflux disease?. 2015 , 28, 23-6	6
1105	Prevalence of gastroesophageal reflux disease in children, adults, and elderly in the same community. 2015 , 30, 1140-6	35
1104	Clinical Improvement of Severe Reflux Esophagitis in Korea: Follow-up Observation by Endoscopy. 2015 , 15, 231	
1103	Predictive factors of response to proton pump inhibitors in korean patients with gastroesophageal reflux disease. 2015 , 21, 69-77	27
1102	Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the national ambulatory medical care survey (2006-2010). 2015 , 2015, 689531	18
1101	Laparoscopic Partial Fundoplication in Case of Gastroesophageal Reflux Disease Patient with Absent Esophageal Motility. 2015 , 15, 127-31	2
1100	The Pathogenesis and Management of Achalasia: Current Status and Future Directions. 2015 , 9, 449-63	65
1099	Managing gastroesophageal reflux disease - comparative efficacy and outcomes of dexlansoprazole MR. 2015 , 11, 1649-56	7
1098	Noncardiac chest pain: update on the diagnosis and management. 2015 , 65, 76-84	7
1097	Analysis of clinical characteristics and causes of chest pain in children and adolescents. 2015 , 58, 440-5	10
1096	Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study. 2015 , 128, 995-9	16
1095	Gastroesophageal reflux disease in COPD: links and risks. 2015 , 10, 1935-49	56
1094	Pantoprazole decreases cell viability and function of human osteoclasts in vitro. 2015 , 2015, 413097	26

1093	Recurrence and Its Impact on the Health-related Quality of Life in Patients with Gastroesophageal Reflux Disease: A Prospective Follow-up Analysis. 2016 , 22, 86-93	12
1092	Gastro-esophageal reflux disease among type-2 diabetes mellitus patients in a rural area. 2015 , 24, 43-9	1
1091	The role of endoscopy in the management of GERD. 2015 , 81, 1305-10	73
1090	Hiatus hernia and gastro-oesophageal reflux disease. 2015 , 43, 192-196	1
1089	Endoluminal treatment for gastroesophageal reflux disease. 2015 , 17, 89-94	
1088	The Effect of Proton Pump Inhibitors on Barrett's Esophagus. 2015 , 44, 415-24	16
1087	Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. 2015 , 42, 649-63	111
1086	Common Mechanism of Pathogenesis in Gastrointestinal Diseases Implied by Consistent Efficacy of Single Chinese Medicine Formula: A PRISMA-Compliant Systematic Review and Meta-Analysis. 2015 , 94, e1111	24
1085	Editorial: alginate-antacid combinations in erosive oesophagitis - picking the acid pocket. Authors' reply. 2015 , 42, 1233	
1084	Outcome of Stretta radiofrequency and fundoplication for GERD-related severe asthmatic symptoms. 2015 , 9, 437-43	8
1083	Gastroesophageal reflux disease is a predictor of atrial fibrillation recurrence following left atrial ablation. 2015 , 183, 211-3	3
1082	Mucosal impedance discriminates GERD from non-GERD conditions. 2015 , 148, 334-43	107
1081	Reply: To PMID 23811248. 2015 , 13, 407-8	3
1080	Underuse of proton-pump inhibitors in older patients newly starting NSAID treatment. 2015 , 69, 791-5	6
1079	Gastroesophageal reflux disease and non-digestive tract diseases. 2015 , 9, 685-92	5
1078	Endoscopic therapies for gastroesophageal reflux disease: back in the game?. 2015 , 148, 280-2	3
1077	Prevalence of benign gastric polyps in a large pathology database. 2015 , 47, 164-9	30
1076	2014 SSAT State-of-the-Art Conference: advances in diagnosis and management of gastroesophageal reflux disease. 2015 , 19, 458-66	14

1075	Laparoscopic adjustable gastric banding outcomes in patients with gastroesophageal reflux disease or hiatal hernia. 2015 , 25, 290-4		11
1074	Management of gastrointestinal involvement in scleroderma. 2015 , 1, 82-105		48
1073	Advances in the evaluation and management of esophageal disease of systemic sclerosis. 2015 , 17, 475		32
1072	Review of gastroesophageal reflux disease (GERD) in the diabetic patient. 2015 , 7, 599-609		10
1071	Rates of reflux before and after laparoscopic sleeve gastrectomy for severe obesity. 2015 , 25, 763-8		53
1070	Medical treatment versus surgery for treatment of gastroesophageal reflux disease. 2015 , 17, 53-61		1
1069	Insult of gastroesophageal reflux on airway: clinical significance of pharyngeal nozzle. 2015 , 9, 117-22		3
1068	Extra-esophageal gastroesophageal reflux disease and asthma: understanding this interplay. 2015 , 9, 969-82		29
1067	Review of Proton Pump Inhibitor Overuse in the US Veteran Population. 2015 , 31, 167-176		4
1066	Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial. 2015 , 22, 26-40		112
1065	Novel surgical options for gastroesophageal reflux disease. 2015 , 9, 943-51		3
1064	Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis. 2015 , 29, 749-758		21
1063	Diagnosis and treatment of benign inflammatory esophageal diseases. 2015 , 47, 188-198		7
1062	How Do US Gastroenterologists Use Over-the-Counter and Prescription Medications in Patients With Gastroesophageal Reflux and Chronic Constipation?. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1516-25	0.7	20
1061	Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. 2015 , 61, 912-7		56
1060	No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. 2015 , 13, 1058-67.e1		99
1059	Preoperative evaluation of gastroesophageal reflux disease. 2015 , 95, 615-27		10
1058	Ambulatory monitoring for gastroesophageal reflux disease: where do we stand?. 2015 , 13, 892-4		3

1057	Gastroesophageal reflux disease after bariatric procedures. 2015 , 95, 579-91	36
1056	Categorization of patients with reflux symptoms referred for pH and impedance testing while off therapy. 2015 , 13, 867-73	13
1055	Metoclopramide role in preventing ileus after cesarean, a clinical trial. 2015 , 71, 657-662	8
1054	Monitoring for GE Reflux: Is Normal the New Normal?. 2015 , 60, 1118-9	
1053	Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study. 2015 , 50, 1173-83	12
1052	More art than science: impedance analysis prone to interpretation error. 2015 , 19, 987-92	5
1051	Computer versus physician identification of gastrointestinal alarm features. 2015 , 84, 1111-7	14
1050	The Role of Baclofen in the Treatment of Gastroesophageal Reflux Disease. 2015 , 31, 258-261	4
1049	Consistent Efficacy of Wendan Decoction for the Treatment of Digestive Reflux Disorders. 2015 , 43, 893-913	11
1048	Esophageal Dysmotility, Gastro-esophageal Reflux Disease, and Lung Transplantation: What Is the Evidence?. 2015 , 17, 48	14
1047	The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. 2015 , 81, 675-682	45
1046	The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. 2015 , 37, 709-16	18
1045	Elevation of the head of bed to treat supraesophageal reflux: controlling the trigger and reducing the "drip". 2015 , 3, 362-4	1
1044	Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. 2015 , 31, 1309-18	10
1043	Development of quality measures for the care of patients with gastroesophageal reflux disease. 2015 , 13, 874-83.e2	16
1042	Long-term cost-effectiveness of medical, endoscopic and surgical management of gastroesophageal reflux disease. 2015 , 157, 126-36	37
1041	Dual Ambulatory pH Monitoring in Patients with Gastroesophageal Reflux Rendered Asymptomatic with Proton Pump Inhibitor Therapy. 2015 , 60, 1343-9	9
1040	Effectiveness of antireflux surgery for the cure of chronic cough associated with gastroesophageal reflux disease. 2015 , 39, 208-15	16

1039	Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. 2015 , 13, 280-6	6
1038	Should the Reflex Be Reflux? Throat Symptoms and Alternative Explanations. 2015 , 13, 1560-6	12
1037	Discrepancies between upper GI symptoms described by those who have them and their identification by conventional medical terminology: a survey of sufferers in four countries. 2016 , 28, 455-62	8
1036	Gastroesophageal reflux disease: A review of surgical decision making. 2016 , 8, 77-83	56
1035	Endoscopic Management of Gastroesophageal Reflux Disease: Revisited. 2016 , 49, 408-416	29
1034	Impact of obesity treatment on gastroesophageal reflux disease. 2016 , 22, 1627-38	46
1033	The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study. 2016 , 16, 204	
1032	Association Between Joint Hypermobility and Gastroesophageal Reflux Disease: An Observational Analytical Cross Sectional Study. 2016 , 31, 188-191	
1031	Effects of Transcutaneous Electrical Acustimulation on Refractory Gastroesophageal Reflux Disease. 2016 , 2016, 8246171	14
1030	Clinical Manifestations of Laryngopharyngeal Reflux. 2016 , 22, 351-2	4
1029	Sex and Gender Differences in Gastroesophageal Reflux Disease. 2016 , 22, 575-588	72
1028	A Model for Predicting the Future Risk of Incident Erosive Esophagitis in an Asymptomatic Population Undergoing Regular Check-ups. 2016 , 95, e2591	2
1027	Transoral incisionless fundoplication: current status. 2016 , 32, 338-43	17
1026	Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain. 2016 , 29, 367-76	3
1025	The association between cardiac and gastrointestinal disorders: causal or casual link?. 2016 , 17, 330-8	12
1024	Tricyclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1037-8	0.7 1
1023	Optimal adaptive two-stage designs for early phase II clinical trials. 2016 , 35, 1257-66	56
1022	Changes in symptom reflux association using dynamic pH thresholds during ambulatory pH monitoring: an observational cross-sectional study. 2016 , 29, 1013-1019	3

1021	Effects of esophageal capsaicin instillation on acid induced excitation of secondary peristalsis in humans. 2016 , 31, 364-9		1
1020	Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. 2016 , 31, 716-26		32
1019	Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy. 2017 , 30, 1-8		19
1018	Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. 2016 , 14, 179		181
1017	Association between Gastroesophageal Reflux Disease and Appendicitis: A Population-Based Case-Control Study. 2016 , 6, 22430		1
1016	Gastroesophageal Reflux Disease. 2016 , 85-90		
1015	General Approach to History-Taking and Physical Examination of the Upper Gastrointestinal Tract. 2016 , 43-45		
1014	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. 2016 , 4, 381-9		140
1013	Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar. 2016 , 38, 1158-73		9
1012	Primary Care Evaluation and Management of Gastroenterologic Issues in Women. 2016 , 43, 347-66		2
1011	Pharmacologic Therapies in Gastrointestinal Diseases. 2016 , 100, 827-50		15
1010	Medical cost, incidence rate, and treatment status of gastroesophageal reflux disease in Japan: analysis of claims data. 2016 , 19, 1049-1055		6
1009	Zero-Inflated Models for Identifying Relationships Between Body Mass Index and Gastroesophageal Reflux Symptoms: A Nationwide Population-Based Study in China. 2016 , 61, 1986-95		1
1008	Long-Term PPI Use: Balancing Potential Harms and Documented Benefits. <i>American Journal of Gastroenterology</i> , 2016 , 111, 913-5	0.7	26
1007	Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study. 2016 , 38, 1392-1400		4
1006	The Race-Specific Incidence of Esophageal Squamous Cell Carcinoma in Individuals With Exposure to Tobacco and Alcohol. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1718-1725	0.7	9
1005	Diagnosis and treatment of gastroesophageal reflux disease: recommendations of the Asociación Mexicana de Gastroenterología. 2016 , 81, 208-222		12
1004	The sensory system of the esophagus--what do we know?. 2016 , 1380, 91-103		6

1003	A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis. 2016 , 36, 985-992	6
1002	Gastroesophageal Disorders. 2016 , 3-16	
1001	Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. 2017 , 30, 1-8	4
1000	Reply. 2016 , 14, 1508	1
999	Diagnosis and treatment of gastroesophageal reflux disease: recommendations of the Asociación Mexicana de Gastroenterología. 2016 , 81, 208-222	2
998	Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease. 2016 , 44, 890-8	85
997	Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. 2016 , 65, 1402-15	98
996	Between GERD and NERD: the relevance of weakly acidic reflux. 2016 , 1380, 218-229	19
995	Consensus Statement of Society of Abdominal Radiology Disease-Focused Panel on Barium Esophagography in Gastroesophageal Reflux Disease. 2016 , 207, 1009-1015	24
994	Achalasia: new perspectives on an old disease. 2016 , 28, 4-11	37
993	The Accuracy of the Laryngopharyngeal Reflux Diagnosis: Utility of the Stroboscopic Exam. 2016 , 155, 629-34	15
992	Reflux and Voice Disorders: Have We Established Causality?. 2016 , 4, 157-167	16
991	Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults. 2016 , 73, S126-32	16
990	Evaluation of a Proton Pump Inhibitor for Sleep Bruxism: A Randomized Clinical Trial. 2016 , 95, 1479-1486	14
989	Laparoscopic vs. open Nissen's fundoplication for gastro-oesophageal reflux disease in children: A meta-analysis. 2016 , 34, 10-16	11
988	Adult and paediatric GERD: diagnosis, phenotypes and avoidance of excess treatments. 2016 , 13, 529-42	16
987	How to Approach Laryngopharyngeal Reflux: An Otolaryngology Perspective. 2016 , 18, 44	17
986	Role of Sleep Apnea and Gastroesophageal Reflux in Severe Asthma. 2016 , 36, 461-71	8

985	Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule. 2016 , 9, 770-780	1
984	Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole. 2016 , 9, 759-769	2
983	The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. 2016 , 6, 32126	8
982	Clinical and pH study characteristics in reflux patients with and without ineffective oesophageal motility (IEM). 2016 , 3, e000126	13
981	Exact p-values for Simon's two-stage designs in clinical trials. 2016 , 8, 351-357	16
980	The suitability of the GERDyzer instrument in pH-test-proven laryngopharyngeal reflux patients. 2016 , 95, e4439	1
979	pH monitoring of gastro-oesophageal reflux before and after laparoscopic sleeve gastrectomy. 2016 , 103, 399-406	34
978	BRAVO esophageal pH monitoring: more cost-effective than empiric medical therapy for suspected gastroesophageal reflux. 2016 , 30, 3454-60	5
977	Influence of replacing percutaneous endoscopic gastrostomy for nasogastric tube feeding on gastroesophageal reflux disease with erosive esophagitis. 2016 , 3, 49-55	
976	The Intersection of GERD, Aspiration, and Lung Transplantation. 2016 , 26, 501-5	33
975	Nickel sensitization in patients with gastro-esophageal reflux disease. 2016 , 4, 184-90	5
974	Effect of a Proton Pump Inhibitor Deprescribing Guideline on Drug Usage and Costs in Long-Term Care. 2016 , 17, 673.e1-4	26
973	Prevalence of allergic rhinitis and asthma in patients with chronic rhinosinusitis and gastroesophageal reflux disease. 2016 , 117, 158-162.e1	15
972	Erstlinienmanagement bei gastroöophagealem Reflux. 2016 , 11, 119-124	
971	Antireflux Surgery and Laryngopharyngeal Reflux. 2016 , 4, 63-66	
970	GERD phenotypes from pH-impedance monitoring predict symptomatic outcomes on prospective evaluation. 2016 , 28, 513-21	32
969	Supragastric belch may be related to globus symptom - a prospective clinical study. 2016 , 28, 680-6	13
968	Prevalence, characteristics, and treatment outcomes of reflux hypersensitivity detected on pH-impedance monitoring. 2016 , 28, 1382-90	30

967	Safety and efficacy of endoscopic spray cryotherapy for Barrett's dysplasia: results of the National Cryospray Registry. 2016 , 29, 241-7		60
966	Lifestyle Intervention in Gastroesophageal Reflux Disease. 2016 , 14, 175-82.e1-3		172
965	Association of interleukin-1B gene polymorphisms at site 511 with gastroesophageal reflux disease: a meta-analysis. 2016 , 13, 74-79		2
964	Results of left thoracoscopic Collis gastroplasty with laparoscopic Nissen fundoplication for the surgical treatment of true short oesophagus in gastro-oesophageal reflux disease and Type III-IV hiatal hernia. 2016 , 49, e22-30		11
963	The American Journal of Gastroenterology in 2016: Where Have We Been? Where Are We Going?. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1-3	0.7	0
962	Analyses of the Post-reflux Swallow-induced Peristaltic Wave Index and Nocturnal Baseline Impedance Parameters Increase the Diagnostic Yield of Impedance-pH Monitoring of Patients With Reflux Disease. 2016 , 14, 40-6		166
961	Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?. 2016 , 5, 169-78		2
960	Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring. 2016 , 31, 350-4		6
959	Improvement of gastroesophageal reflux disease in Japanese patients with spinal kyphotic deformity who underwent surgical spinal correction. 2016 , 28, 50-8		11
958	Nissen Sleeve (N-Sleeve) operation: preliminary results of a pilot study. 2016 , 12, 1832-1837		54
957	Effect of Timing of Proton Pump Inhibitor Administration on Acid Suppression. 2016 , 93, 111-20		10
956	Risk factors for Barrett's esophagus: a scoping review. 2016 , 27, 301-23		10
955	Evaluation of the relationship between major dietary patterns and uninvestigated reflux among Iranian adults. 2016 , 32, 573-83		9
954	A Modern Approach to the Surgical Treatment of Gastroesophageal Reflux Disease. 2016 , 26, 174-9		6
953	An Episode Payment Framework for Gastroesophageal Reflux Disease: Symptomatic Gastroesophageal Reflux Disease, Dysplastic and Nondysplastic Barrett's Esophagus, and Anti-Reflux Surgical and Endoscopic Interventions. 2016 , 150, 1009-18		1
952	GERD: An Alternative Perspective. 2016 , 57, 142-51		4
951	Oropharyngeal Reflux Monitoring and Atypical Gastroesophageal Reflux Disease. 2016 , 18, 12		12
950	Laryngopharyngeal reflux: diagnosis, treatment and latest research. 2016 , 48, 74-91		6

949	An Episode Payment Framework for Gastroesophageal Reflux Disease. 2016 , 150, 1019-25	1
948	Videostroboscopy, Laryngopharyngeal Reflux, and Dysphonia: A Complex Relationship. 2016 , 4, 49-54	1
947	Effects of poor asthma control, insomnia, anxiety and depression on quality of life in young asthmatics. 2016 , 53, 398-403	29
946	Outcomes of fundoplication for paediatric gastroesophageal reflux disease. 2016 , 32, 353-61	11
945	Role of H2RA and Proton Pump Inhibitor Therapy in Treating Reflux Disease. 2016 , 71-91	2
944	Estimation of the symptoms for GERD by GerdQ in the patients with rheumatic diseases. 2016 , 26, 265-70	
943	Definitions of Gastroesophageal Reflux Disease (GERD). 2016 , 1-17	1
942	Diagnostic Approaches to GERD. 2016 , 37-57	
941	Pulmonary Complications of Abdominal Diseases. 2016 , 1639-1652.e4	
940	Boundary problem in Simon's two-stage clinical trial designs. 2017 , 27, 25-33	11
939	Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. 2017 , 52, 444-451	70
938	Study of Gender Differences in Proton Pump Inhibitor Dose Requirements for GERD: A Double-Blind Randomized Trial. 2017 , 51, 486-493	9
937	Effectiveness and Tolerability of Different Recommended Doses of PPIs and HRAs in GERD: Network Meta-Analysis and GRADE system. 2017 , 7, 41021	12
936	Do sleeve gastrectomy and gastric bypass influence treatment with proton pump inhibitors 4 years after surgery? A nationwide cohort. 2017 , 13, 951-959	28
935	Quality of life, patient satisfaction, and disease burden in patients with gastroesophageal reflux disease with or without laryngopharyngeal reflux symptoms. 2017 , 32, 1336-1340	14
934	A Modern Magnetic Implant for Gastroesophageal Reflux Disease. 2017 , 15, 1326-1337	18
933	Post-fundoplication symptoms and complications: Diagnostic approach and treatment. 2017 , 82, 234-247	13
932	American Society for Metabolic and Bariatric Surgery: care pathway for laparoscopic sleeve gastrectomy. 2017 , 13, 742-749	39

931	Improved control of hypertension following laparoscopic fundoplication for gastroesophageal reflux disease. 2017 , 11, 68-73	2
930	The Changing Impact of Gastroesophageal Reflux Disease in Clinical Practice. 2017 , 126, 229-235	10
929	The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. 2017 , 77, 547-561	38
928	Fluoroscopic studies of the upper gastrointestinal tract: techniques and indications. 2017 , 59, 343-354	
927	Symptoms, endoscopic findings and reflux monitoring results in candidates for bariatric surgery. 2017 , 49, 750-756	17
926	The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. 2017 , 152, 706-715	378
925	Evaluation of Gastroesophageal Reflux Disease. 2017 , 41, 1672-1677	6
924	Moderating the Enthusiasm of Sleeve Gastrectomy: Up to Fifty Percent of Reflux Symptoms After Ten Years in a Consecutive Series of One Hundred Laparoscopic Sleeve Gastrectomies. 2017 , 27, 1797-1803	68
923	Risk factors associated with gastroesophageal reflux disease relapse in primary care patients successfully treated with a proton pump inhibitor. 2017 , 82, 106-114	1
922	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. 2017 , 93, 415-423	43
921	The Right Idea for the Wrong Patient: Results of a National Survey on Stopping PPIs. 2017 , 15, 1475-1476	4
920	Should I continue taking my acid reflux medication? Design of a pilot before/after study evaluating a patient decision aid. 2017 , 150, 19-23	6
919	Does my patient still have reflux when ppi therapy does not work?. 2017 , 29, e13065	1
918	Utility of esophageal mucosal impedance as a diagnostic test for esophageal disease. 2017 , 33, 277-284	13
917	Manifestations atypiques du reflux gastro-œsophagien (RGO) et maladies allergiques, les liaisons dangereuses. 2017 , 57, 341-347	1
916	Outcomes of magnetic sphincter augmentation - A community hospital perspective. 2017 , 213, 1019-1023	15
915	New Approaches to Gastroesophageal Reflux Disease. 2017 , 21, 1544-1552	21
914	Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients. 2017 , 6,	14

913	Complications of Proton Pump Inhibitor Therapy. 2017 , 153, 35-48	228
912	An innovative mindfulness and educational care approach in an adult patient affected by gastroesophageal reflux: the IARA model. 2017 , 14,	9
911	ACG and CAG Clinical Guideline: Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , 2017 , 112, 988-1013	0.7 259
910	Gastroesophageal reflux disease: Dichotomy of the clinical trial and clinical practice. 2017 , 82, 103-105	
909	World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. 2017 , 51, 467-478	78
908	Classification of esophageal motor findings in gastro-esophageal reflux disease: Conclusions from an international consensus group. 2017 , 29, e13104	130
907	Postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance can link PPI-responsive heartburn to reflux better than acid exposure time. 2017 , 29, e13116	87
906	Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives. 2017 , 62, 1881-1889	42
905	Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. 2017 , 153, 702-710	82
904	Implementation of a proton pump inhibitor stewardship program. 2017 , 74, 932-937	7
903	Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. 2017 , 29, 1-15	194
902	Exercise for Multimorbid Patients in Primary Care: One Prescription for All?. 2017 , 47, 2143-2153	6
901	Post-fundoplication symptoms and complications: Diagnostic approach and treatment. 2017 , 82, 234-247	2
900	White Paper AGA: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease. 2017 , 15, 1162-1172	15
899	Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo wireless esophageal pH monitoring study. 2017 , 82, 277-286	2
898	GERD Management: The Case for Lifestyle in an Era of PPIs. 2017 , 11, 24-28	0
897	Risk factors associated with gastroesophageal reflux disease relapse in primary care patients successfully treated with a proton pump inhibitor. 2017 , 82, 106-114	6
896	Deprescribing versus continuation of chronic proton pump inhibitor use in adults. 2017 , 3, CD011969	53

895	Medical Treatment of Gastroesophageal Reflux Disease. 2017 , 41, 1678-1684	11
894	Recent advances in diagnostic testing for gastroesophageal reflux disease. 2017 , 11, 531-537	6
893	Gastroesophageal reflux disease: Dichotomy of the clinical trial and clinical practice. 2017 , 82, 103-105	
892	Gastroesophageal Reflux Disease (GERD). 2017 , 125-132	
891	Association between 24-hour combined multichannel intraluminal impedance-pH monitoring and symptoms or quality of life in patients with laryngopharyngeal reflux. 2017 , 42, 584-591	18
890	Snus and risk of gastroesophageal reflux. A population-based case-control study: the HUNT study. 2017 , 52, 193-198	2
889	The Quality of Care for Gastroesophageal Reflux Disease. 2017 , 62, 569-576	9
888	Medicinal Plants for Management of Gastroesophageal Reflux Disease: A Review of Animal and Human Studies. 2017 , 23, 82-95	10
887	Mucosal Biopsy After Bone Marrow Transplantation. 2017 , 10, 909-930	4
886	Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. 2017 , 96, e8120	10
885	In response to the commentary of Dr. Lou on treatment of laryngopharyngeal reflux using a sleep positioning device: A prospective cohort study. 2017 , 38, 726-727	
884	Omeprazole-Domperidone Fixed Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease. 2017 , 10, 1179552217709456	6
883	Multichannel Intraluminal Impedance and pH Monitoring (pH-MII) in Infants and Children. 2017 , 89-110	
882	Diabetes and the Esophagus. 2017 , 15, 475-489	7
881	Endoscopic anti-reflux devices (with videos). 2017 , 86, 931-948	19
880	Evaluation of treatment pattern and symptom control in patients with gastroesophageal reflux disease: multihospital questionnaire survey on the current situation in Korea. 2017 , 30, 1-8	1
879	Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease. 2017 , 127 Suppl 6, S1-S13	27
878	Preoperative diagnosis of hiatal hernia: barium swallow X-ray, high-resolution manometry, or endoscopy?. 2017 , 49, 210-217	22

877	Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease. 2017 , 31, 501-508	44
876	Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease. 2017 , 62, 3059-3068	5
875	An analysis of 342 patients with refractory gastroesophageal reflux disease symptoms using questionnaires, high-resolution manometry, and impedance-pH monitoring. 2017 , 96, e5906	6
874	Dysphagia in the Elderly. 2017 , 15, 382-396	10
873	Gastrointestinal Disturbances in the Elderly. 2017 , 52, 419-431	6
872	Prevalence and Clinical Characteristics of Gastroesophageal Reflux Disease in Human Immunodeficiency Virus Infected Adults. 2017 , 25, 29-32	
871	Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. 2017 , 19, 46	23
870	Monte Carlo Simulation Used to Calculate Energy Correction Factor for Thermoluminescent Dosimeters Used by Occupational Workers on Pediatric Exams. 2017 , 177, 223-242	
869	Magnetically recoverable nano-catalysts in sulfoxidation reactions. 2017 , 6, 549-571	28
868	Vocal Cord Dysfunction and Asthma. 2017 , 4, 329-341	3
867	Safety and Efficacy of Wireless pH Monitoring in Patients Suspected of Gastroesophageal Reflux Disease: A Systematic Review. 2017 , 51, 777-788	8
866	Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. 2017 , 62, 3298-3316	12
865	Gastroesophageal Reflux Disease. 2017 , 44, 561-573	35
864	Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo wireless esophageal pH monitoring study. 2017 , 82, 277-286	
863	Acupuncture for the treatment of gastro-oesophageal reflux disease: a systematic review and meta-analysis. 2017 , 35, 316-323	61
862	Treatment of laryngopharyngeal reflux using a sleep positioning device: A prospective cohort study. 2017 , 38, 603-607	5
861	Bidirectional association between fibromyalgia and gastroesophageal reflux disease: two population-based retrospective cohort analysis. 2017 , 158, 1971-1978	7
860	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. 2017 , 5, 591-598	47

859	Oral Manifestations of Gastrointestinal Disorders. 2017 , 25, 93-104	4
858	The added diagnostic value of postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on-therapy impedance-pH monitoring. 2017 , 29, e12947	84
857	Gastritis, Esophagitis, and Peptic Ulcer Disease. 2017 , 1131-1139	
856	Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis. 2017 , 29, e12926	37
855	The Problem of Gastroesophageal Reflux Disease and Hiatal Hernia. 2017 , 165-172	
854	Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. 2017 , 70, 203-210	39
853	Association Between Response to Acid-Suppression Therapy and Efficacy of Antireflux Surgery in Patients With Extraesophageal Reflux. 2017 , 15, 675-681	24
852	Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. <i>American Journal of Gastroenterology</i> , 2017 , 112, 95-101	0.7 42
851	Prevalence of dental erosion among people with gastroesophageal reflux disease in China. 2017 , 117, 48-54	9
850	The clinical significance of hypercontractile peristalsis: comparison of high-resolution manometric features, demographics, symptom presentation, and response to therapy in patients with Jackhammer esophagus versus Nutcracker esophagus. 2017 , 30, 1-7	17
849	System design and experimental research of lower esophageal sphincter stimulator for treatment of gastroesophageal reflux disease. 2017 , 2017, 2177-2180	2
848	Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. 2017 , 30, 1-9	64
847	Gastroesophageal Reflux Disease. 2017 , 1-17	
846	Low yield for non-targeted biopsies of the stomach and esophagus during elective esophagogastroduodenoscopy. 2017 , 5, E1268-E1277	2
845	Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. 2018 , 31, 1-7	19
844	A Double-blind, Randomized, Multicenter Clinical Trial Investigating the Efficacy and Safety of Esomeprazole Single Therapy Versus Mosapride and Esomeprazole Combined Therapy in Patients with Esophageal Reflux Disease. 2017 , 23, 218-228	14
843	Gastro-Esophageal Reflux in Children. 2017 , 18,	26
842	A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease. 2017 , 2017, 9865963	9

841	First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. 2017 , 23, 8395-8404	4
840	Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. 2017 , 10, 5053-5064	17
839	Morbidity and mortality associated with obesity. 2017 , 5, 161	341
838	Nissen fundoplication proton pump inhibitors for laryngopharyngeal reflux based on pH-monitoring and symptom-scale. 2017 , 23, 3546-3555	15
837	Alcohol and tea consumption are associated with asymptomatic erosive esophagitis in Taiwanese men. 2017 , 12, e0173230	22
836	Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. 2017 , 12, e0171006	44
835	Dietary habits and obesity indices in patients with gastro-esophageal reflux disease: a comparative cross-sectional study. 2017 , 17, 132	14
834	Use of proton pump inhibitors in general practice. 2017 , 8, 180-185	12
833	Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration. 2017 , 10, 47-56	3
832	25 Years of Proton Pump Inhibitors: A Comprehensive Review. 2017 , 11, 27-37	204
831	Factors leading to dyspepsia in renal transplant recipients. 2017 , 28, 120	4
830	Psychological Results of 438 Patients with persisting Gastroesophageal Reflux Disease Symptoms by Symptom Checklist 90-Revised Questionnaire. 2017 , 7, 117-121	18
829	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline. 2017 , 35, 1606-1621	79
828	New Eosinophilic Esophagitis Concepts Call for Change in Proton Pump Inhibitor Management Before Diagnostic Endoscopy. 2018 , 154, 1217-1221.e3	12
827	Suppressed hydration in metoclopramide hydrochloride by salt cocrystallisation. 2018 , 20, 2653-2662	13
826	Endoscopic management of refractory gastroesophageal reflux disease. 2018 , 53, 390-397	14
825	Non-operative Treatment of Gastroesophageal Reflux Disease. 2018 , 1-15	
824	Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. 2018 , 66, 1332-1338	33

823	Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn. <i>American Journal of Gastroenterology</i> , 2018 , 113, 670-676	0.7	44
822	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. 2018 , 14, 447-460		62
821	Peroral endoscopic cardiac constriction in gastroesophageal reflux disease. 2018 , 97, e0169		11
820	Optimisation of follow-up after metabolic surgery. 2018 , 6, 487-499		29
819	Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis. 2018 , 154, 1298-1308.e7		76
818	Extraesophageal Symptoms and Diseases Attributed to GERD: Where is the Pendulum Swinging Now?. 2018 , 16, 1018-1029		34
817	Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. 2018 , 66, 516-554		359
816	Heartburn. 2018 , 53, 18-25		2
815	The psychological results of 438 patients with persisting GERD symptoms by Symptom Checklist 90-Revised (SCL-90-R) questionnaire. 2018 , 97, e9783		6
814	Practice Differences in the Diagnosis and Management of Eosinophilic Esophagitis Among Adult and Pediatric Gastroenterologists in Israel. 2018 , 67, 34-39		5
813	Endoscopic Treatments of GERD. 2018 , 16, 58-71		4
812	Esophagography and gastroesophageal reflux disease: utilization and utility. 2018 , 43, 1306-1307		1
811	Modern diagnosis of GERD: the Lyon Consensus. 2018 , 67, 1351-1362		532
810	Surgical management of gastroesophageal reflux disease in patients with systemic sclerosis. 2018 , 32, 3855-3860		19
809	Refractory Heartburn: A Challenging Problem in Clinical Practice. 2018 , 63, 577-582		5
808	Other Predisposing Factors for Bronchiectasis. 2018 , 129-145		1
807	Multifaceted intervention to curb in-hospital over-prescription of proton pump inhibitors: A longitudinal multicenter quasi-experimental before-and-after study. 2018 , 50, 52-59		8
806	High Prevalence of Barrett's Esophagus and Esophageal Squamous Cell Carcinoma After Repair of Esophageal Atresia. 2018 , 16, 513-521.e6		25

805	Gastroesophageal Reflux in the Intensive Care Unit Patient. 2018 , 30, 123-135	1
804	Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. 2018 , 63, 302-311	32
803	Laryngopharyngeal Reflux: Current Concepts on Etiology and Pathophysiology and Its Role in Dysphagia. 2018 , 6, 196-202	2
802	Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study). 2018 , 33, 1722-1727	1
801	A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis-Phase III clinical trial. 2018 , 68, 67-71	0
800	New food approaches to reduce and/or eliminate increased gastric acidity related to gastroesophageal pathologies. 2018 , 54, 26-32	13
799	Salivary Pepsin Test: Useful and Simple Tool for the Laryngopharyngeal Reflux Diagnosis. 2018 , 69, 80-85	4
798	Getting into a TIF(F) Over Fundoplication. 2018 , 154, 1227-1228	1
797	A comparative study of ranitidine and quince (<i>Cydonia oblonga</i> mill) sauce on gastroesophageal reflux disease (GERD) in pregnancy: a randomised, open-label, active-controlled clinical trial. 2018 , 38, 899-905	25
796	PPI Trial for Eosinophilic Esophagitis: Chaos in the Community. 2018 , 52, 590-595	5
795	Patient Values and Preferences Surrounding Proton Pump Inhibitor Use: A Scoping Review. 2018 , 11, 17-28	14
794	The Esophageal Epithelial Barrier in Health and Disease. 2018 , 16, 608-617	26
793	Long-Term Outcomes of Laparoscopic Sleeve Gastrectomy-a Single-Center, Retrospective Study. 2018 , 28, 130-134	49
792	Salivary Pepsin Test: Useful and simple tool for the laryngopharyngeal reflux diagnosis. 2018 , 69, 80-85	7
791	Esophageal function testing: Billing and coding update. 2018 , 30, e13158	4
790	Defining GERD in Asia: Different from the West?. 2018 , 1-11	
789	Gastroesophageal reflux disease: A clinical overview for primary care physicians. 2018 , 25, 1-11	14
788	Nonerosive Reflux Disease (NERD). 2018 , 109-134	

787	I Am Tired of Taking Pills for My Reflux, What Else Can I Do? Surgical and Endoscopic Treatment for GERD. 2018 , 143-152	
786	Esophageal Chest Pain: Esophageal Spasm. 2018 , 25-37	
785	Regurgitation. 2018 , 101-108	
784	Gastrointestinal Involvement in Systemic Sclerosis: An Update. 2018 , 24, 328-337	27
783	Gastrointestinal and Hepatic Disease in Systemic Sclerosis. 2018 , 44, 15-28	26
782	Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months. 2018 , 87, 1405-1412.e3	71
781	Association of Proton Pump Inhibitor Use With Serum Biomarkers of Inflammation, Insulin Resistance, Cardiovascular Risk, and Renal Function. 2018 , 52, 691-695	1
780	Oral microbiome alterations of healthy volunteers with proton pump inhibitor. 2018 , 33, 1059-1066	37
779	Appropriate Use of Proton Pump Inhibitors: A Double-Edged Sword. 2018 , 131, 218-219	1
778	Asthma, GERD and Obesity: Triangle of Inflammation. 2018 , 85, 887-892	17
777	Assessing Old and New Diagnostic Tests for Gastroesophageal Reflux Disease. 2018 , 154, 289-301	33
776	Management of Gastroesophageal Reflux Disease. 2018 , 154, 302-318	149
775	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary. 2018 , 14, 167-171	11
774	Gastro-oesophageal reflux disease and eosinophilic oesophagitis: What is the relationship?. 2018 , 9, 63-72	1
773	Practice styles, knowledge and attitudes of general practitioners and gastroenterology specialists who treat gastroesophageal reflux disease. 2018 , 97, e13781	2
772	Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. 2018 , 31, 639-648	37
771	Clinical Practice Guidelines for Diagnosis and Management of Cough-Chinese Thoracic Society (CTS) Asthma Consortium. 2018 , 10, 6314-6351	40
770	Fiber-enriched diet helps to control symptoms and improves esophageal motility in patients with non-erosive gastroesophageal reflux disease. 2018 , 24, 2291-2299	29

769	Proton pump inhibitors for chronic obstructive pulmonary disease. 2018,	1
768	The Clinical Relevance of Gastroesophageal Reflux Disease and Laryngopharyngeal Reflux in Clinical Practice. 2018,	
767	Introduction: Discovery: A Path to a New Solution for Gastroesophageal Reflux Disease. 2018, xvii-xxxii	
766	Model to Select On-Therapy vs Off-Therapy Tests for Patients With Refractory Esophageal or Extraesophageal Symptoms. 2018, 155, 1729-1740.e1	15
765	Confounders of severe asthma: diagnoses to consider when asthma symptoms persist despite optimal therapy. 2018, 11, 29	11
764	Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence. 2018, 13, e0205644	10
763	The overlap syndrome of urticaria and gastroesophageal reflux disease. 2018, 13, e0207602	5
762	A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015. 2018, 13, e0208461	11
761	Endoscopic techniques for treating gastroesophageal reflux. 2018, 34, 288-294	1
760	Endoluminal Approaches to Gastroesophageal Reflux Disease. 2018, 28, 527-532	6
759	Wireless 24, 48, and 96 Hour or Impedance or Oropharyngeal Prolonged pH Monitoring: Which Test, When, and Why for GERD?. 2018, 20, 52	12
758	Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment. 2018, 35, 2024-2040	
757	Gastroesophageal Reflux. 2018, 15, 9-20	
756	Risk factors for gastroesophageal reflux disease and analysis of genetic contributors. 2018, 6, 176-182	25
755	Current Trends in the Management of Gastroesophageal Reflux Disease. 2018, 12, 7-16	88
754	Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies. 2018, 96, 571-587	10
753	Diagnostic yield of ambulatory oesophageal studies on versus off proton pump inhibitors: a systematic review and meta-analysis. 2018, 6, 1294-1306	0
752	ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?. 2018, 55Suppl 1, 85-91	7

751	Proton Pump Inhibitors: Are They a Real Threat to the Patient?. 2018 , 25, 243-252	4
750	Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe. 2018 , 11, 381-389	
749	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. 2018 , 155, 1022-1033.e10	367
748	Gastroesophageal Reflux Disease. 2018 , 437-450	
747	Prevalence of infection in sexual partners of infected subjects: Role of gastroesophageal reflux. 2018 , 6, 1470-1476	13
746	Esophageal Baseline Impedance Reflects Mucosal Integrity and Predicts Symptomatic Outcome With Proton Pump Inhibitor Treatment. 2018 , 24, 43-50	13
745	Nonerosive reflux disease: clinical concepts. 2018 , 1434, 290-303	7
744	Current and future perspectives in the management of gastroesophageal reflux disease. 2018 , 1434, 70-83	4
743	Relevance of histology in the diagnosis of reflux esophagitis. 2018 , 1434, 94-101	3
742	Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial. 2018 , 36, 257-263	4
741	The role of esophageal pH-impedance testing in clinical practice. 2018 , 34, 249-257	8
740	Indications and interpretation of esophageal function testing. 2018 , 1434, 239-253	28
739	Intra- and interobserver variability in the diagnosis of GERD by real-time MRI. 2018 , 104, 14-19	9
738	Chronic Cough Is Associated With Long Breaks in Esophageal Peristaltic Integrity on High-resolution Manometry. 2018 , 24, 387-394	13
737	Acotiamide Has No Effects on Esophageal Motor Activity or Esophagogastric Junction Compliance. 2018 , 24, 241-247	4
736	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. 2018 , 2018, 7572430	9
735	Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors. 2018 , 8, 9949	17
734	Hiatal Hernia Repair in Difficult Pathologic-Anatomic Situations at the Hiatus. 2018 , 433-437	

733	Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms. 2018 , 63, 2673-2680	4
732	Efficacy and Safety of Traditional Chinese Medicine on Nonerosive Reflux Disease: A Meta-Analysis of Randomized Controlled Trials. 2018 , 2018, 1505394	10
731	Gastroesophageal reflux symptoms among Italian university students: epidemiology and dietary correlates using automatically recorded transactions. 2018 , 18, 116	15
730	Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. 2018 , 11, 119-134	35
729	Evaluation of gastroesophageal reflux disease. 2018 , 70, 309-313	9
728	Designing a novel antacid for sensitive populations. 2018 , 9, 257-258	
727	Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. 2018 , 33, 614-624	32
726	A Nationwide Population-Based Cohort Study of Dementia Risk Among Acid Suppressant Users. 2018 , 26, 1175-1183	15
725	Esophageal motility disorders. 2018 , 20, 98-106	
724	The pharmacological treatment of chronic comorbidities in COPD: mind the gap!. 2018 , 51, 48-58	5
723	Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. 2018 , 269-291	3
722	Proton-pump inhibitors among adults: a nationwide drug-utilization study. 2018 , 11, 1756284818777943	54
721	Chest Pain: If It Is Not the Heart, What Is It?. 2018 , 53, 421-431	0
720	Respiratory care in familial dysautonomia: Systematic review and expert consensus recommendations. 2018 , 141, 37-46	8
719	Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis: AGREE conference. 2018 , 121, 281-284	45
718	A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk. 2018 , 141, 132-143	12
717	Reflux Finding Score (RFS) a Quantitative Guide for Diagnosis and Treatment of Laryngopharyngeal Reflux. 2018 , 70, 362-365	4
716	A Prospective Study of Eosinophilic Esophagitis and the Expression of Tight Junction Proteins in Patients with Gastroesophageal Reflux Disease Symptoms. 2018 , 12, 30-37	7

715	Preoperative Gastroesophageal Reflux Disorder Is Associated With Increased Morbidity in Patients Undergoing Abdominal Surgery. 2018 , 232, 587-594		1
714	THE ROLE OF THE TRANSDIAPHRAGMATIC PRESSURE GRADIENT IN THE PATHOPHYSIOLOGY OF GASTROESOPHAGEAL REFLUX DISEASE. 2018 , 55Suppl 1, 13-17		9
713	Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents. 2018 , 320, 650-656		28
712	Clinical measurement of gastrointestinal motility and function: who, when and which test?. 2018 , 15, 568-579		25
711	Utility of Water Siphon Maneuver for Eliciting Gastroesophageal Reflux During Barium Esophagography: Correlation With Histologic Findings. 2018 , 211, 335-339		1
710	Complications of Antireflux Surgery. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1137-1147	0.7	46
709	The Proton Pump Inhibitor Nonresponder: a Behavioral Approach to Improvement and Wellness. 2018 , 20, 34		11
708	Dyspepsia and peptic ulcer disease. 2018 , 401-410		1
707	Systemic sclerosis-associated interstitial lung disease: Role of the oesophagus in outcomes. 2018 , 23, 885-886		3
706	Specific Features of Gastroesophageal Reflux Disease in Patients with Overweight (Basis for Personalized Treatment). 2018 , 165, 213-215		
705	Introduction into the NHS of magnetic sphincter augmentation: an innovative surgical therapy for reflux - results and challenges. 2018 , 100, 251-256		8
704	Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease. 2018 , 13, e0197400		8
703	Tissue Sampling, Specimen Handling, and Laboratory Processing. 2019 , 51-68.e6		2
702	Gastroesophageal Reflux Disease. 2019 , 268-278.e3		
701	Effect of right lateral position with head elevation on tracheal aspirate pepsin in ventilated preterm neonates: randomized controlled trial. 2019 , 32, 3741-3746		1
700	Management of Refractory Gastroesophageal Reflux Disease #377. 2019 , 22, 998-1000		0
699	Relationship between esophageal motility and severity of gastroesophageal reflux disease according to the Los Angeles classification. 2019 , 98, e15543		14
698	Predicting factors of recurrence in patients with gastroesophageal reflux disease: a prospective follow-up analysis. 2019 , 12, 1756284819864549		3

697	Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD. 2019 , 54, 1083-1095	11
696	The Mexican consensus on non-cardiac chest pain. 2019 , 84, 372-397	
695	Impact of procedural multimedia instructions for pH BRAVO testing on patient comprehension: a prospective randomized study. 2020 , 33,	2
694	Natural history of gastroesophageal reflux: A prospective cohort study in a stratified, randomized population in Beijing. 2019 , 20, 523-531	0
693	Frequent Sips of the Water for the Management of Gastroesophageal Reflux Induced Refractory Cough: A Case Report and Review of the Literature. 2019 , 2019, 9205259	0
692	Popular Remedies for Esophageal Symptoms: a Critical Appraisal. 2019 , 21, 39	3
691	Treatment of newly-diagnosed gastroesophageal reflux disease: a nationwide register-based cohort study. 2019 , 54, 830-837	3
690	Preoperative esophagogastroduodenoscopy in patients without reflux symptoms undergoing laparoscopic sleeve gastrectomy: utility or futility?. 2019 , 12, 295-301	2
689	The Utility of Esophageal Motility Testing in Gastroesophageal Reflux Disease (GERD). 2019 , 21, 37	11
688	Updates in the field of non-esophageal gastroesophageal reflux disorder. 2019 , 13, 827-838	18
687	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. 2019 , 157, 682-691.e2	181
686	Ameliorating Effects of Transcutaneous Electrical Acustimulation Combined With Deep Breathing Training on Refractory Gastroesophageal Reflux Disease Mediated via the Autonomic Pathway. 2019 , 22, 751-757	4
685	Surgical Treatment for Gastroesophageal Reflux Disease: Is It Effective Even for Asians?. 2019 , 25, 337-339	0
684	Reflux Esophagitis and Barrett Esophagus. 2019 , 41-67	
683	In search of the grail: A race for acid suppression. 2019 , 84, 344-356	
682	GastroÖophageale Refluxerkrankung und geschlechtsspezifische Unterschiede. 2019 , 14, 96-101	
681	Chinese medicine JQ granule combined with half-dose omeprazole for nonerosive reflux disease: A multicenter, randomized, double-blind, placebo-controlled trial study protocol. 2019 , 31, 100974	1
680	Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. 2019 , 381, 1513-1523	85

679	Lifestyle intervention for gastroesophageal reflux disease: a national multicenter survey of lifestyle factor effects on gastroesophageal reflux disease in China. 2019 , 12, 1756284819877788	14
678	The Patient with Heartburn or Chest Pain. 2019 , 13-21	
677	Etiology and Natural History of Gastroesophageal Reflux Disease and Predictors of Progressive Disease. 2019 , 204-220	7
676	Novel therapies for gastroesophageal reflux disease. 2019 , 56, 100692	1
675	Managing End-Stage Renal Disease: An Alphabetized Mnemonic Strategy. 2019 , 15, 732-736	1
674	Therapeutic Efficacy of Kangfuxin Liquid Combined with PPIs in Gastric Ulcer. 2019 , 2019, 1324969	3
673	Problems Associated with Deprescribing of Proton Pump Inhibitors. 2019 , 20,	20
672	Objective tongue color and gastroesophageal reflux disease: Cross-sectional study. 2019 , 6, 19-25	2
671	Laparoscopic repair of hiatal hernia. 2019 , 11, 3903-3908	3
670	Survey of nocturnal reflux in patients with gastroesophageal reflux disease in China. 2019 , 20, 589-595	
669	HISTORICAL PERSPECTIVE OF GASTROESOPHAGEAL REFLUX DISEASE CLINICAL TREATMENT. 2019 , 56, 202-208	1
668	Correlates of gastroenterology health-services utilization among patients with gastroesophageal reflux disease: a large database analysis. 2019 , 8, 66	3
667	Proton pump inhibitors, adverse events and increased risk of mortality. 2019 , 18, 1043-1053	26
666	Validity and reliability of the Quality of Life in Reflux and Dyspepsia (QoLRAD) questionnaire in patients with gastroesophageal reflux disease for the Turkish population. 2019 , 30, 511-516	1
665	Management of Gastroesophageal Reflux Disease in the Elderly Patient. 2019 , 36, 1073-1081	6
664	In search of the grail: A race for acid suppression. 2019 , 84, 344-356	0
663	Validation of the Korean Version of the Gastroesophageal Reflux Disease Questionnaire for the Diagnosis of Gastroesophageal Reflux Disease. 2019 , 25, 91-99	10
662	Advances in the Diagnosis and Treatment of GERD: New Tricks for an Old Disease. 2019 , 17, 1-17	4

661	Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial. 2019 , 25, 2110-2121	11
660	The Mexican consensus on non-cardiac chest pain. 2019 , 84, 372-397	1
659	Gastric bypass surgery in the treatment of gastro-oesophageal reflux symptoms. 2019 , 50, 159-166	34
658	Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. 2019 , 58, 2427-2433	8
657	Laryngopharyngeal Reflux. 2019 , 3-11	
656	CLINICAL AND ENDOSCOPIC EVALUATION IN PATIENTS WITH GASTROESOPHAGEAL SYMPTOMS. 2019 , 56, 51-54	2
655	Heartburn. 2019 , 107-120	
654	Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. 2019 , 19, 84	17
653	Polymorphisms of the BARX1 and ADAMTS17 Locus Genes in Individuals With Gastroesophageal Reflux Disease. 2019 , 25, 436-441	1
652	Diagnosis and Management of Gastroesophageal Reflux Disease in Infants and Children: from Guidelines to Clinical Practice. 2019 , 22, 107-121	21
651	Radiofrequency ablation is safe and effective in the treatment of Chinese patients with gastroesophageal reflux disease: A single-center prospective study. 2019 , 20, 229-234	2
650	[Gastroesophageal Reflux Disease]. 2019 , 73, 70-76	4
649	Melatonin for the treatment of gastroesophageal reflux disease; protocol for a systematic review and meta-analysis. 2019 , 98, e14241	4
648	Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. 2019 , 49, 864-872	23
647	Clinical and psychological characteristics in gastroesophageal reflux disease patients overlapping with laryngopharyngeal reflux symptoms. 2019 , 34, 1720-1726	6
646	Sociedade Portuguesa de Cuidados Intensivos guidelines for stress ulcer prophylaxis in the intensive care unit. 2019 , 31, 5-14	3
645	Impact of Chronic Statins Use on the Development of Esophagitis in Patients with Gastroesophageal Reflux Disease. 2019 , 2019, 6415757	2
644	Gastrointestinal Health and Healthy Aging. 2019 , 67-79	

643	Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. 2019 , 150, 66-73	9
642	Gastrointestinal Involvement of Systemic Sclerosis. 2019 , 123-136	
641	Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. 2019 , 24, e12586	5
640	What is the impact of metabolic syndrome and its components on reflux esophagitis? A cross-sectional study. 2019 , 19, 33	5
639	Overlap Between GERD and Functional Esophageal Disorders-a Pivotal Mechanism for Treatment Failure. 2019 , 17, 161-164	8
638	Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment. 2019 , 42, 20-28	25
637	Potentially inappropriate medications according to STOPP-J criteria and risks of hospitalization and mortality in elderly patients receiving home-based medical services. 2019 , 14, e0211947	16
636	Real-time MRI for the dynamic assessment of fundoplication failure in patients with gastroesophageal reflux disease. 2019 , 29, 4691-4698	7
635	Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study. 2019 , 39, 443-453	37
634	The management of hiatal hernia: an update on diagnosis and treatment. 2019 , 92, 321-325	14
633	pH and Impedance Evaluation of the Esophagus. 2019 , 129-140	
632	Educational Case: Noninfectious Esophagitis.. 2019 , 6, 2374289519893087	
631	Clinical and Quality of Life Assessment of Patients Undergoing Laparoscopic Hiatal Hernia Repair. 2019 , 85, 1269-1275	1
630	Zhujie Hwei Granules Ameliorated Reflux Esophagitis in Rats. 2019 , 2019, 1392020	3
629	COPD and Comorbidities: Relating Mechanisms and Treatment. 2019 , 15, 90-101	1
628	Acupuncture for refractory gastro-oesophageal reflux disease: a systematic review and meta-analysis protocol. 2019 , 9, e030713	2
627	Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. 2019 , 9, 17280	20
626	Why differences between New York and New Delhi matter in approach to gastroesophageal reflux disease. 2019 , 38, 371-377	2

625	Gastrointestinal Involvement in Systemic Sclerosis: Overview, Neglected Aspects, Malnutrition, Body Composition and Management. 2019 ,	
624	The Clinician's Guide to Proton-Pump Inhibitor Discontinuation. 2019 , 53, 553-559	1
623	Tailored modern GERD therapy - steps towards the development of an aid to guide personalized anti-reflux surgery. 2019 , 9, 19174	5
622	Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network meta-analysis. 2019 , 12, 1756284819890537	10
621	Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. 2019 , 38, 411-440	13
620	GASTROESOPHAGEAL REFLUX DISEASE. 2019 , 42, 185-188	2
619	True Short Esophagus in Gastroesophageal Reflux Disease: Old Controversies With New Perspectives. 2021 , 274, 331-338	1
618	Effectiveness of transoral incisionless fundoplication compared to Toupet fundoplication for chronic or refractory gastroesophageal reflux disease: a systematic review protocol. 2019 , 17, 507-512	1
617	Safety of Over-the-Counter Medications in Pregnancy. 2019 , 44, 196-205	3
616	Association between Lifestyle and Gastroesophageal Reflux Disease Questionnaire Scores: A Cross-Sectional Study of 37 442 Chinese Adults. 2019 , 2019, 5753813	5
615	Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem. 2019 , 21, 65	7
614	A Randomized Placebo-Controlled -of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease. 2019 , 2019, 3926051	1
613	Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial. 2019 , 89, 14-22.e1	61
612	Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: A multicentric cohort study. 2019 , 7, 189-198	19
611	Refractory regurgitation responds to magnetic sphincter augmentation but not to increased proton pump inhibitor dose. 2019 , 89, 23-24	2
610	Reflux symptoms in professional opera soloists. 2019 , 51, 798-803	2
609	Trajectory assessment is useful when day-to-day esophageal acid exposure varies in prolonged wireless pH monitoring. 2019 , 32,	8
608	High-risk symptoms do not predict gastric cancer precursors. 2019 , 24, e12548	7

607	Endoscopic magnet placement into subadventitial tunnels for augmenting the lower esophageal sphincter using submucosal endoscopy: ex vivo and in vivo study in a porcine model (with video). 2019 , 89, 422-428	5
606	Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents. 2019 , 64, 493-502	2
605	Gastroesophageal and Laryngopharyngeal Reflux Associated With Laryngeal Malignancy: A Systematic Review and Meta-analysis. 2019 , 17, 1253-1264.e5	32
604	Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. 2019 , 103, 15-27	28
603	Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders. 2019 , 17, 1073-1080.e1	28
602	Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors. 2019 , 160, 70-76	11
601	Asthma medication usage is significantly reduced following bariatric surgery. 2019 , 33, 1967-1975	14
600	Concomitant Hiatal Hernia Repair Is more Common in Laparoscopic Sleeve Gastrectomy than During Laparoscopic Roux-en-Y Gastric Bypass: an Analysis of 130,772 Cases. 2019 , 29, 744-746	18
599	Changes in the distal esophageal microbiota in Chinese patients with reflux esophagitis. 2019 , 20, 18-24	9
598	Five common errors to avoid in clinical practice: the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Choosing Wisely Campaign. 2019 , 14, 301-308	2
597	Topiramate-Induced Chest Pain: A Case Report. 2019 , 32, 236-239	0
596	Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. 2019 , 68, 374-376	17
595	Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. 2020 , 29 Suppl 1, 26-34	6
594	Natural history, pathophysiology and evaluation of gastroesophageal reflux disease. 2020 , 66, 100848	22
593	Management of gastroesophageal reflux disease. 2020 , 66, 100849	3
592	Gastroesophageal Reflux Disease (GERD) in Children. 2020 , 682-691	1
591	Optimizing bariatric surgery outcomes: a novel preoperative protocol in a bariatric population with gastroesophageal reflux disease. 2020 , 34, 1812-1818	12
590	Higher clinical suspicion is needed for prompt diagnosis of esophageal adenocarcinoma in young patients. 2019 ,	4

589	Clinical Outcomes of Minimally Invasive Enucleation of Leiomyoma of the Esophagus and Esophagogastric Junction. 2020 , 24, 499-504	10
588	Magnetic Sphincter Augmentation Superior to Proton Pump Inhibitors for Regurgitation in a 1-Year Randomized Trial. 2020 , 18, 1736-1743.e2	21
587	Hiatal Hernias. 2020 , 209-217	
586	Magnetic sphincter augmentation (MSA) in patients with hiatal hernia: clinical outcome and patterns of recurrence. 2020 , 34, 1835-1846	12
585	Coffee to go? The effect of coffee on resolution of ileus following abdominal surgery: A systematic review and meta-analysis of randomised controlled trials. 2020 , 39, 1385-1394	8
584	No association between proton pump inhibitor use and risk of dementia: Evidence from a meta-analysis. 2020 , 35, 19-28	8
583	Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. 2020 , 69, 224-230	29
582	Surgical management of gastroesophageal reflux disease in the obese patient. 2020 , 34, 450-457	7
581	New treatment method for refractory gastroesophageal reflux disease (GERD): C-BLART (clip band ligation anti-reflux therapy)-a short-term study. 2020 , 34, 4516-4524	5
580	Treatment Pattern and Economic Burden of Refractory Gastroesophageal Reflux Disease Patients in Korea. 2020 , 26, 281-288	9
579	Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns?. 2020 , 51, 121-128	8
578	Acute administration of fructans increases the number of transient lower esophageal sphincter relaxations in healthy volunteers. 2020 , 32, e13727	4
577	Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study. 2020 , 32, e13749	3
576	Erosive Esophagitis Portends a Benign Clinical Course in the Majority of Patients. 2020 , 65, 3244-3252	0
575	Role of Multimodality Imaging in Gastroesophageal Reflux Disease and Its Complications, with Clinical and Pathologic Correlation. 2020 , 40, 44-71	2
574	Decreasing Overall and Inappropriate Proton Pump Inhibitor Use: Perspective From a Large Safety-Net Healthcare System. 2020 , 18, 763-766.e2	7
573	Esophageal dysmotility and other preoperative factors associated with acid suppressive therapy after fundoplication. 2020 , 55, 1-8	2
572	Gastroesophageal Reflux Disease (GERD). 2020 , 672-681	

571	No Association Linking Short-Term Proton Pump Inhibitor Use to Dementia: Systematic Review and Meta-analysis of Observational Studies. <i>American Journal of Gastroenterology</i> , 2020 , 115, 671-678	0.7	11
570	Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux?: A Systematic Review and Meta-analysis. 2020 , 271, 257-265		115
569	Achalasia. 2020 , 213-223		
568	Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy. 2020 , 54, 227-234		6
567	Association Between Beverage Intake and Incidence of Gastroesophageal Reflux Symptoms. 2020 , 18, 2226-2233.e4		22
566	Effect of Catgut Embedment in Du Meridian Acupoint on Mental and Psychological Conditions of Patients with Gastroesophageal Reflux Disease. 2020 , 2020, 5415813		1
565	Acupuncture at the dorsal section of the governor vessel for gastroesophageal reflux disease combined with sleep disorder: A research of case series. 2020 , 30, 229-232		
564	Characterization of intragastric pressure waveform in endoscopic pressure study integrated system: Novel diagnostic device for gastroesophageal reflux disease. 2021 , 33, 780-787		2
563	Safety and feasibility of transesophageal echocardiography in patients with prior esophageal surgery. 2020 , 37, 1430-1435		1
562	The fraction of sensitization among lung transplant recipients in a transplant center in Japan. 2020 , 20, 256		2
561	Impact of head of bed elevation in symptoms of patients with gastroesophageal reflux disease: A randomized single-blind study (IBELGA). 2020 , 43, 310-321		
560	Esophageal physiology-an overview of esophageal disorders from a pathophysiological point of view. 2020 , 1481, 182-197		0
559	Endoscopy in Extraesophageal Manifestations Secondary to Gastroesophageal Reflux Disease: Why Do We Insist?. 2020 , 27, 302-303		1
558	Reflux Hypersensitivity: How to Approach Diagnosis and Management. 2020 , 22, 42		5
557	Non-acid Reflux: When It Matters and Approach to Management. 2020 , 22, 43		4
556	The Mediterranean Diet in Gastrointestinal and Liver Diseases. 2020 , 18, 718-728		1
555	Varlı de 87 a�s con impacta�ı esof�gica. 2020 , 13, 417e1-417e3		
554	Laryngopharyngeal Reflux: A State-of-the-Art Algorithm Management for Primary Care Physicians. 2020 , 9,		8

553	Prolonged Wireless pH Monitoring or 24-Hour Catheter-Based pH Impedance Monitoring: Who, When, and Why?. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1150-1152	0.7	1
552	A retrospective study on prescribing pattern and cost analysis of proton-pump inhibitors used among adults of Saudi Arabia. 2020 , 11, 343-347		0
551	Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls. 2020 , 11, 1000		9
550	Tongue diagnosis indices for gastroesophageal reflux disease: A cross-sectional, case-controlled observational study. 2020 , 99, e20471		5
549	Esophageal Evaluation for Patients Undergoing Lung Transplant Evaluation: What Should We Do for Evaluation and Management. 2020 , 49, 451-466		
548	Extra-Esophageal Presentation of Gastroesophageal Reflux Disease: 2020 Update. 2020 , 9,		12
547	A model for the pandemic and beyond: Telemedicine for all outpatient gastroenterology referrals reduces unnecessary clinic visits. 2020 , 1357633X20957224		5
546	Dysphonia and reflux in children: A systematic review. 2020 , 139, 110473		4
545	Low prevalence of upper endoscopic gastrointestinal findings despite high frequency of alarm symptoms at the time of diagnosis in adult coeliac disease. 2020 , 32, 1447-1451		1
544	Rethinking gastroesophageal reflux disorder. 2020 , 1482, 177-192		1
543	Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. 2020 , 15, e0237676		7
542	Relevance of proton pump inhibitors prescriptions in a tertiary care hospital in Lebanon. 2020 , 21, 194-198		0
541	Design and Experimental Research of Implantable Lower Esophageal Sphincter Stimulator Based on Android Bluetooth. 2020 , 2020, 5220-5223		1
540	GERD for the nongastroenterologist: successful evaluation, management, and lifestyle-based symptom control. 2020 , 1482, 106-112		1
539	Proton pump inhibitors for chronic obstructive pulmonary disease. 2020 , 8, CD013113		6
538	Gastrointestinal pharmacology: practical tips for the esophagologist. 2020 , 1481, 90-107		6
537	Perioperative screening, management, and surveillance of Barrett's esophagus in bariatric surgical patients. 2020 , 1481, 224-235		2
536	The burden of gastroesophageal reflux disease on the cost of managing chronic diseases in Australia. The need for a new diagnostic and management paradigm. 2020 , 1742395320966373		

535	Long-term patient satisfaction and durability of laparoscopic anti-reflux surgery in a large Danish cohort: study protocol for a retrospective cohort study with development of a novel scoring system for patient selection. 2020 , 10, e034257	1
534	Upper Endoscopy in Patients with Extra-Oesophageal Reflux Symptoms: A Multicentre Study. 2020 , 27, 312-317	0
533	Quality indicators in diagnostic upper gastrointestinal endoscopy. 2020 , 13, 1756284820916693	9
532	Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. 2020 , 35, 2096-2102	
531	Stretta radiofrequency treatment vs Toupet fundoplication for gastroesophageal reflux disease: a comparative study. 2020 , 20, 162	4
530	How to apply the personalized medicine in obesity-associated asthma?. 2020 , 14, 905-915	2
529	Physicians' adherence to management guidelines for H. pylori infection and gastroesophageal reflux disease: a cross-sectional study. 2020 , 9, 28	1
528	Is it time to revisit surgery and endoscopic therapy for refractory GERD?. 2020 , 92, 88-90	
527	How to advise patients on the risk of chronic proton pump inhibitor therapy. 2020 , 36, 317-322	5
526	A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. 2020 , 52, 966-980	9
525	The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. 2020 , 76, 1437-1456	2
524	Impedance in the evaluation of the esophagus. 2020 , 1481, 139-153	1
523	Proton Pump Inhibitors: for What and for How Long. 2020 , 2, 719-726	
522	Efficacy and Safety of Dor Fundoplication in Patients with Severe Gastroparesis and Refractory Gastroesophageal Reflux Disease. 2020 , 2, 134-139	2
521	Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. 2020 , 76, 851-866	11
520	The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 2020 , 5, 561-581	29
519	Predictors of dental erosions in patients evaluated with upper digestive endoscopy: a cross-sectional study. 2020 , 108, 723-729	3
518	Personalized Approach in the Work-up and Management of Gastroesophageal Reflux Disease. 2020 , 30, 227-238	12

517	Refractory Gastroesophageal Reflux Disease and Functional Heartburn. 2020 , 30, 343-359	9
516	Erosive Esophagitis and Symptoms of Gastroesophageal Reflux Disease in Patients with Morbid Obesity with and without Type 2 Diabetes: a Cross-sectional Study. 2020 , 30, 2667-2675	4
515	Ten Things Every Gastroenterologist Should Know About Antireflux Surgery. 2020 , 18, 1923-1929	3
514	The Lyon Consensus: Does It Differ From the Previous Ones?. 2020 , 26, 311-321	13
513	Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment. 2020 , 49, 437-450	5
512	Esophageal contractile segment impedance from high-resolution impedance manometry correlates with mean nocturnal baseline impedance and acid exposure time from 24-hour pH-impedance monitoring. 2020 , 33,	5
511	New developments in esophageal function testing and esophageal manifestations of connective tissue disorders. 2020 , 1481, 170-181	1
510	Clinical-Pathological Conference Series from the Medical University of Graz : Case No 171: A 37-year-old engineer with bolus hold-up (esophageal food impaction). 2020 , 132, 551-559	
509	A Model Using Clinical and Endoscopic Characteristics Identifies Patients at Risk for Eosinophilic Esophagitis According to Updated Diagnostic Guidelines. 2021 , 19, 1824-1834.e2	2
508	Differences in Management of Eosinophilic Esophagitis in Europe: An Assessment of Current Practice. 2020 , 71, 83-90	11
507	Utilidad clínica de la determinación de pepsina en saliva en pacientes con tos crónica asociada a reflujo. 2020 , 2, 11-16	
506	Anti-Heartburn Effects of Sugar Cane Flour: A Double-Blind, Randomized, Placebo-Controlled Study. 2020 , 12,	2
505	Proton Pump Inhibitor-Induced Galactorrhea in a Kidney Transplant Recipient: A Friend or Foe?. 2020 , 2020, 8108730	2
504	Genetic evidence that higher central adiposity causes gastro-oesophageal reflux disease: a Mendelian randomization study. 2020 , 49, 1270-1281	7
503	Mucosal impedance for esophageal disease: evaluating the evidence. 2020 , 1481, 247-257	5
502	Management of Peptic Strictures. <i>American Journal of Gastroenterology</i> , 2020 , 115, 967-970	0.7 2
501	Medicine and Media: The Ranitidine Debate. 2020 , 13, 649-651	9
500	The Nissen-Sleeve (N-Sleeve): Results of a Cohort Study. 2020 , 30, 3267-3272	17

499	New Developments in the Diagnosis and Management of Gastroesophageal Reflux. 2020 , 18, 69	1
498	IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. 2020 , 158, 2093-2103	20
497	Increased prevalence of Barrett's esophagus in patients with MUTYH-associated polyposis (MAP). 2020 , 19, 183-187	0
496	Relationship between laryngopharyngeal reflux disease and gastroesophageal reflux disease based on synchronous esophageal and oropharyngeal Dx-pH monitoring. 2020 , 41, 102441	4
495	Proton Pump Inhibitors: The Good, Bad, and Ugly. 2020 , 30, 239-251	11
494	Prolonged Wireless pH Monitoring in Patients With Persistent Reflux Symptoms Despite Proton Pump Inhibitor Therapy. 2020 , 18, 2912-2919	8
493	Editorial: moving towards appropriate use of proton pump inhibitors. Authors' reply. 2020 , 51, 177	
492	In Barrett's epithelial cells, weakly acidic bile salt solutions cause oxidative DNA damage with response and repair mediated by p38. 2020 , 318, G464-G478	4
491	Real-time MRI for dynamic assessment of gastroesophageal reflux disease: Comparison to pH-metry and impedance. 2020 , 125, 108856	0
490	Tojapride Reverses Esophageal Epithelial Inflammatory Responses on Reflux Esophagitis Model Rats. 2021 , 27, 604-612	1
489	Efficacy of a new nutraceutical formulation (CHETGERD) in patients with nonerosive reflux disease (NERD): a prospective observational study. 2020 , 15, 1265-1269	
488	Cost-effective Management of Severe Gastroesophageal Reflux Disease: Toward an Improved Understanding of Anti-reflux Surgery. 2020 , 26, 169-170	0
487	Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions. 2020 , 12,	9
486	Gastroesophageal reflux disease in a typical African population: a symptom-based multicenter study. 2020 , 20, 107	4
485	Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea. 2020 , 26, 215-223	9
484	Use of Proton Pump Inhibitors Increases Risk of Incident Kidney Stones. 2021 , 19, 72-79.e21	5
483	Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. 2021 , 66, 19-28	16
482	Early outcomes of peroral endoscopic myotomy with fundoplication for achalasia cardia - Is it here to stay?. 2021 , 33, 561-568	3

481	Current status of laparoscopic bariatric/metabolic surgery in Japan: The sixth nationwide survey by the Japan Consortium of Obesity and Metabolic Surgery. 2021 , 14, 170-177	10
480	Three-year clinical experience with magnetic sphincter augmentation and laparoscopic fundoplication. 2021 , 35, 3449-3458	4
479	Differentiation of Clinical Patterns Associated With Rhinologic Disease. 2021 , 35, 179-186	1
478	Approach to the Patient with Cough. 2021 , 105, 31-38	
477	Gastroesophageal Reflux Disease and Barrett Esophagus in the Elderly. 2021 , 37, 17-29	2
476	The Natural Course of Gastroesophageal Reflux Disease: A Critical Appraisal of the Literature. 2021 , 55, 12-20	1
475	Microscopic Esophageal Sloughing Is Not Specific to "Sloughing Esophagitis". 2021 , 155, 895-902	
474	[Upper abdominal pain: a frequent and multifaceted leading symptom in primary care internal medicine]. 2021 , 62, 3-16	
473	Prevalence of gastro-oesophageal reflux symptoms: An Italian cross-sectional survey focusing on knowledge and attitudes towards lifestyle and nutrition. 2021 , 75, e13758	2
472	The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). 2021 , 22, 219-227	5
471	Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial. 2021 , 160, 174-182.e1	13
470	Effect of Head-of-Bed Elevation on Nocturnal Reflux Symptoms of Esophageal Cancer Patients With Esophagectomy and Reconstruction. 2021 , 44, 244-250	2
469	Impact of nurse practitioner navigation on access to care for patients with refractory gastroesophageal reflux disease. 2021 , 33, 77-85	
468	Gastroesophageal Reflux Disease: Workup and Evaluation. 2021 , 1-9	
467	Gastroesophageal reflux disease: recent innovations in endoscopic assessment and treatment. 2021 , 9, 383-391	1
466	Correlation between pre-operative endoscopic findings with reflux symptom score for gastro-oesophageal reflux disease in bariatric patients. 2021 , 17, 322-328	0
465	The Gastroesophageal Disease and Its Association to Ear, Nose, Throat Complaints. 2021 , 10, 337-344	
464	Gastroesophageal Disorders. 2021 , 1-15	

- 463 Prätherapeutische Evaluation bei gastroösophagealer Refluxerkrankung und Hiatushernie. **2021**, 115-124
- 462 The Medical Management of Gastroesophageal Reflux Disease: A Narrative Review. **2021**, 12, 21501327211046736
- 461 Esophageal pH increments associated with post-reflux swallow-induced peristaltic waves show the occurrence and relevance of esophago-salivary reflex in clinical setting. **2021**, 33, e14085 5
- 460 Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis. **2021**, 14, 1756284821998928 8
- 459 Gastroesophageal Reflux Disease. **2021**, 171-176 0
- 458 Sphincter Augmentation and Management of Gastroesophageal Reflux with the LINX® Device and Sleeve Gastrectomy. **2021**, 287-311
- 457 Inhibitory effects of *Camellia japonica* on cell inflammation and acute rat reflux esophagitis. **2021**, 16, 6 2
- 456 Gastroösophageale Refluxkrankheit. **2021**, 29-40
- 455 Diagnostic workup and indications for antireflux surgery. **2021**, 1, 13
- 454 Gastrointestinal Tract: Assessment and Treatment of Cough. **2021**, 47-54
- 453 Salivary microbiome with gastroesophageal reflux disease and treatment. **2021**, 11, 188 9
- 452 Pneumatic dilation for persistent dysphagia after antireflux surgery, a multicentre single-blind randomised sham-controlled clinical trial. **2022**, 71, 10-15 6
- 451 Prophylactic Surgery for Benign Diseases of Stomach and Duodenum. **2021**, 163-172
- 450 Knowledge and practice of family medicine and internal medicine residents toward the management of gastroesophageal reflux disease in Riyadh, Saudi Arabia. **2021**, 10, 3005-3012
- 449 When does proton pump inhibitor treatment become long term? A scoping review. **2021**, 8, 2
- 448 Extra-esophageal symptoms in individuals with and without erosive esophagitis: a case-control study in Albania. **2021**, 21, 76
- 447 Surgical treatment of recalcitrant gastroesophageal reflux disease in patients with systemic sclerosis: a systematic review. **2021**, 406, 1353-1361 1
- 446 Cognition, oxidative stress and vitamin B12 levels evaluation on patients under long-term omeprazole use. **2021**, 1

445	Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan. 2021 , 22, 237-245	3
444	Efficacy of different endoscopic treatments in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis. 2021 , 35, 1500-1510	3
443	The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection. 2021 , 12,	3
442	Novel Interdisciplinary Approach to GERD: Concomitant Laparoscopic Hiatal Hernia Repair with Transoral Incisionless Fundoplication. 2021 , 232, 309-318	12
441	Diagnosis and treatment of superior mesenteric artery compression syndrome complicated with gastroesophageal reflux disease. 2021 , 134, 1382-1384	
440	Peculiarities of surgical treatment of patients with gastroesophageal reflux disease. 2021 , 88, 3-7	
439	Surgical treatment of GERD: systematic review and meta-analysis. 2021 , 35, 4095-4123	8
438	Estimate of Refractory Reflux Disease in the United States: Economic Burden and Associated Clinical Characteristics. 2021 , 55, 842-850	3
437	Diagnosis and Treatment of Esophageal Chest Pain. 2021 , 18-37	
436	The role of magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease. 2021 , 37, 384-389	3
435	Preoperative physiological esophageal assessment for anti-reflux surgery: A guide for surgeons on high-resolution manometry and pH testing. 2021 , 27, 1751-1769	1
434	Refractory Heartburn. 2021 , 444-464	
433	Utilization of Long-term Ambulatory Reflux Monitoring as a Guide for Future Treatment in Gastroesophageal Reflux Disease with Inappropriate Response to Proton Pump Inhibitors. 2021 , 77, 202-203	
432	Prediction of Target-Drug Therapy by Identifying Gene Mutations in Lung Cancer With Histopathological Stained Image and Deep Learning Techniques. 2021 , 11, 642945	1
431	Clinical Spectrum and Diagnosis of GERD Phenotypes. 2021 , 333-346	
430	Impact of bariatric surgery on gastroesophageal reflux disease and esophageal motility. 2021 , 37, 364-371	2
429	Understanding the most commonly billed diagnoses in primary care: Gastroesophageal reflux disease. 2021 , 46, 50-55	0
428	Association of patient gender and gastroenterologists' diagnosis and management choices in gastroesophageal reflux disease. 2021 , 34,	

427	Impact of Overlapping Functional Gastrointestinal Disorders on the Quality of Life in Patients With Gastroesophageal Reflux Disease. 2021 , 27, 176-184	3
426	A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease. 2021 , 27, 165-175	5
425	Esophageal Involvement and Gastroesophageal Reflux Disease in Systemic Sclerosis: A Tertiary Center Experience.	
424	Acid Suppression Use Among Infants in One Tertiary Children's Hospital in China, 2015-2018: A Retrospective Observational Study. 2021 , 9, 679203	0
423	Effect of rose oil on Gastroesophageal Reflux Disease in comparison with omeprazole: A double-blind controlled trial. 2021 , 43, 101361	2
422	Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between. 2021 , 1, 145-151	
421	ASMBS position statement on the rationale for performance of upper gastrointestinal endoscopy before and after metabolic and bariatric surgery. 2021 , 17, 837-847	14
420	Role of extract as medicinal food on reflux esophagitis in rats. 2021 , 9, 3114-3122	0
419	Gastroesophageal reflux disease: new approaches to optimizing pharmacotherapy. 2021 , 30-37	
418	Low FODMAPs diet or usual dietary advice for the treatment of refractory gastroesophageal reflux disease: An open-labeled randomized trial. 2021 , 33, e14181	2
417	Lifestyle Management of Gastroesophageal Reflux Disease: Evidence-Based Approaches to Improve Patient Care. 2021 , 1, 139-144	0
416	The Value of Reflux Monitoring: The Old and the New for the Diagnosis and Assessment of GERD. 2021 , 1, 124-131	1
415	The management of upper gastrointestinal symptoms: A study on community pharmacies in Italy. 2021 , 68, 401-409	1
414	A Randomized Open-Label Study of Two Methods of Proton Pump Inhibitors Discontinuation. 2021 , 13, e15022	
413	Omeprazole-clopidogrel interaction and neurovascular complications after flow-diverter device placement. 2021 ,	0
412	Caracterizaci3n de los trastornos manom3tricos esof3gicos en pacientes con enfermedad por reflujo gastroesof3gico refractario con s3ntomas esof3gicos. 2021 , 36, 212-217	
411	Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus. 2021 , 54, 412-418	14
410	Assessing the Merits of a PPI Trial-Based Diagnosis for Gastroesophageal Reflux Disease: Speculations on Efficacy and Pitfalls. 2021 , 1, 110-114	

409	Mortality, Reoperation, and Hospital Stay Within 90 Days of Primary and Secondary Antireflux Surgery in a Population-Based Multinational Study. 2021 , 160, 2283-2290	2
408	Minimal Invasive Surgery for Gastroesophageal Reflux Disease and Hiatus Hernia Our Experience: A Case Series with Review of Literature.	
407	Gastro-oesophageal reflux disease. 2021 , 7, 55	6
406	Degree of concordance on the management of patients with gastroesophageal reflux disease. A study among specialists that are members of the Sociedad Latinoamericana de Neurogastroenterología (SLNG). 2021 ,	
405	Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. 2021 , 54, 402-411	5
404	Simultaneous determination of proton pump inhibitors by high performance liquid chromatography with resonance Rayleigh scattering: A study of mechanism, performance and application. 2021 , 166, 106259	0
403	Redo fundoplication and early Roux-en-Y diversion for failed fundoplication: a 3-year single-center experience. 2021 , 1	1
402	Nontuberculous Mycobacteria. 2021 , 42, 567-586	3
401	Microaspiration in GER as one of the causes of bronchial asthma exacerbation and the occurrence of chronic cough in children. History of the problem and diagnostics. 2021 , 20, 97-102	
400	Chinese expert consensus on gastroesophageal reflux disease in 2020. 2021 , 22, 376-389	4
399	Consensus statements and recommendations on the management of mild-to-moderate gastroesophageal reflux disease in the Southeast Asian region. 2021 , 5, 855-863	1
398	Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects. 2021 ,	0
397	Esophageal manifestation in patients with scleroderma. 2021 , 9, 5408-5419	0
396	Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study. 2021 , 185, 106491	7
395	Gastrointestinal manifestations of systemic sclerosis: An updated review. 2021 , 9, 6201-6217	1
394	Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters. 2021 ,	6
393	Response of Laryngopharyngeal Symptoms to Transoral Incisionless Fundoplication in Patients with Refractory Proven Gastroesophageal Reflux. 2021 , 34894211037414	1
392	Comparison of Hematoxylin & Eosin (H&E) Staining And Periodic Acid Schiff-Alcian Blue (Pas-AB) Histochemistry in Esophageal Biopsies In Terms of Intestinal Metaplasia.	

- 391 Sorting out the Relationship between Gastroesophageal Reflux Disease and Sleep. **2021**, 23, 15 3
- 390 The features of GERD pharmacotherapy. **2021**, 5-24
- 389 Role of Neuromodulators for the Management of Post-Gastric-Fundoplication Dyspepsia: A Retrospective Series. **2021**, 13, e18343
- 388 Association of eosinophil-mediated inflammatory biomarkers with the presence of the Schatzki ring. **2021**, 66, 279-283
- 387 Influence of gastric morphology on gastroesophageal reflux in adults: An observational study. **2021**, 100, e27241
- 386 Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. **2021**, 156, 190-201 1
- 385 Refractory Gastroesophageal Reflux Disease. **2021**, 6, 613-623 0
- 384 A urine and serum metabolomics study of gastroesophageal reflux disease in TCM syndrome differentiation using UPLC-Q-TOF/MS. **2021**, 206, 114369 0
- 383 Receipt of treatment among a nationally representative sample of US adults with communication disorders. **2021**, 94, 106148 0
- 382 Gastrointestinal System. **2022**, 307-403 0
- 381 Diagnosis and treatment of reflux hypersensitivity with gastroesophageal reflux symptoms from a surgical perspective. 2,
- 380 Differentiated approach to the choice of PPI in a patient with GERD in the practice of an outpatient (with a clinical case). **2021**, 118-125
- 379 Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: The first report of allele *17. **2021**, 16, e0245401 1
- 378 Gastroesophageal Reflux Disease. **2021**, 24-45
- 377 Long-Term Health-Related Quality of Life (HRQoL) After Redo-Fundoplication. **2021**, 45, 1495-1502 3
- 376 Poor consistency between reflux symptom index and laryngopharyngeal pH monitoring in laryngopharyngeal reflux diagnosis in Chinese population. **2021**, 9, 25 1
- 375 Evaluation and Management of Patients with PPI-Refractory Heartburn. **2021**, 19, 134-152
- 374 Head of bed elevation to relieve gastroesophageal reflux symptoms: a systematic review. **2021**, 22, 24 1

373	Association of a standardized measure of nasopharyngeal inflammation with Eustachian tube dysfunction questionnaire score. 2021 , 11, 1177-1186	0
372	Gastroesophageal Reflux Disease: A Review. 2020 , 324, 2536-2547	46
371	Gastroesophageal Reflux Disease. 2015 , 37-47	1
370	Establishing the Diagnosis of GERD. 2017 , 13-18	1
369	The Relationship Between Asthma and Gastro-Esophageal Reflux. 2018 , 137-164	1
368	Gastroesophageal Reflux Disease (GERD) and COPD. 2018 , 165-174	1
367	Anti-reflux Procedures and Cardioresophagomyotomy. 2015 , 51-58	1
366	Anxiety Disorders and Medical Comorbidity: Treatment Implications. 2020 , 1191, 237-261	15
365	Provider Variability in the Management Patterns of Increased Nonacid Reflux. 2021 , 66, 994-998	0
364	Impact of head of bed elevation in symptoms of patients with gastroesophageal reflux disease: a randomized single-blind study (IBELGA). 2020 , 43, 310-321	4
363	Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. 2017 , 14, 665-676	112
362	Antireflux mucosectomy band in treatment of refractory gastroesophageal reflux disease: a pilot study for safety, feasibility and symptom control. 2020 , 8, E147-E154	12
361	Short Meal-to-Bed Time Is a Predominant Risk Factor of Gastroesophageal Reflux Disease in Pregnancy. 2021 , 55, 316-320	2
360	Normal acid exposure time in esophageal pH monitoring in Asian and Western populations: A systematic review and meta-analysis. 2021 , 33, e14029	2
359	Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy. 2016 , 57, 546-551	6
358	Current therapies for gastro-oesophageal reflux in the setting of chronic lung disease: state of the art review. 2020 , 6,	6
357	Costunolide inhibits inflammation in LPS-induced RAW264.7 cells and ameliorates gastric acid reflux-induced esophageal injury in rat model. 2020 , 63,	4
356	Upper aerodigestive tract disorders and gastro-oesophageal reflux disease. 2015 , 3, 102-11	13

355	LINX reflux management system to bridge the "treatment gap" in gastroesophageal reflux disease: A systematic review of 35 studies. 2020 , 8, 294-305	12
354	Diagnosis and Anti-Reflux Therapy for GERD with Respiratory Symptoms: A Study Using Multichannel Intraluminal Impedance-pH Monitoring. 2016 , 11, e0160139	10
353	Evaluation and Validation of the Modified Reflux Symptom Questionnaire-Electronic Diary in Patients With Persistent Gastroesophageal Reflux Disease. 2020 , 11, e00117	1
352	Association of Potentially Inappropriate Medications With All-Cause Mortality in the Elderly Acute Decompensated Heart Failure Patients: Importance of Nonsteroidal Anti-Inflammatory Drug Prescription. 2020 , 11, 239-246	2
351	Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics. 2019 , 12, 305-311	2
350	Prevalence and Correlates of Gastroesophageal Reflux Disease in Southern Iran: Pars Cohort Study. 2017 , 9, 129-138	6
349	[Esophageal achalasia]. 2019 , 72-77	2
348	[Possibilities of pH impedance and high-resolution manometry in managing patients with refractory gastroesophageal reflux disease]. 2017 , 89, 76-83	10
347	Non-prescription proton-pump inhibitors for self-treating frequent heartburn:the role of the Canadian pharmacist. 2016 , 14, 868	2
346	The management of gastro-oesophageal reflux disease. 2016 , 39, 6-10	9
345	Chapter 13: Heartburn and Dyspepsia. 2017 ,	1
344	Management of the COPD Patient with Comorbidities: An Experts Recommendation Document. 2020 , 15, 1015-1037	18
343	Application of Transition Metals in Sulfoxidation Reactions. 2020 , 17, 423-449	26
342	Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. 2020 , 30, 70-97	38
341	Diagnosis of GERD in typical and atypical manifestations. 2018 , 89, 33-39	5
340	[Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection]. 2019 , 91, 4-11	8
339	Microbiome and Gastroesophageal Disease: Pathogenesis and Implications for Therapy. 2020 , 4, 020-033	4
338	Inhibition or Reversal of the Epithelial-Mesenchymal Transition in Gastric Cancer: Pharmacological Approaches. 2020 , 22,	10

337	Perceptions of patient-centered care among Veterans with gastroesophageal reflux disease on proton pump inhibitor therapy. 2018 , 5, 149-159	0
336	Revision of failed transoral incisionless fundoplication by subsequent laparoscopic Nissen fundoplication. 2014 , 20, 17115-9	13
335	Autofluorescence imaging endoscopy can distinguish non-erosive reflux disease from functional heartburn: A pilot study. 2016 , 22, 3845-51	7
334	Oropharyngeal acid reflux and motility abnormalities of the proximal esophagus. 2016 , 22, 8991-8998	13
333	Effects of Chinese herbal medicine Xiangbin prescription on gastrointestinal motility. 2017 , 23, 2987-2994	8
332	Advances in the Diagnosis of GERD Using the Esophageal pH Monitoring, Gastro-Esophageal Impedance-pH Monitoring, And Pitfalls. 2018 , 6, 1934-1940	5
331	Feasibility of Laparoscopic Management of Hiatal Hernia and/or Gastroesophageal Reflux Disease with Laparoscopic Sleeve Gastrectomy or Greater Curvature Plication in Morbidly Obese Patients. 2016 , 11, 54-61	1
330	A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough. 2016 , 8, 178-85	19
329	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. 2020 , 41, 250-255	2
328	Ethanol extract of Magnolia sieboldii buds ameliorated esophageal tissue injury induced by gastric acid reflux in rats via regulating the nuclear factor- κ B signaling pathway. 2020 , 16, 161	2
327	Esophageal surgery in minimally invasive era. 2016 , 8, 52-64	13
326	Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors. 2016 , 8, 719-728	7
325	Proposed approach to the challenging management of progressive gastroesophageal reflux disease. 2018 , 10, 175-183	15
324	Potential role of new technological innovations in nonvariceal hemorrhage. 2019 , 11, 443-453	7
323	Weight Management as a Treatment Option for Gastroesophageal Reflux Disease: A Mechanical or Metabolic Rescuer?. 2018 , 12, 607-608	1
322	The Risk of Acute Myocardial Infarction in Patients With Gastroesophageal Reflux Disease. 2020 , 26, 471-476	2
321	Refractory chronic cough due to gastroesophageal reflux: Definition, mechanism and management. 2015 , 5, 149-56	16
320	Effects of Pistacia lentiscus and Coriander Triphala on Adult Gastroesophageal Reflux Disease: A Randomized Double-Blinded Clinical Trial. 2020 , 22,	1

319	The Effect of Myrtus communis L. Syrup in Reducing the Recurrence of Gastroesophageal Reflux Disease: A Double-Blind Randomized Controlled Trial. 2017 , 19,	2
318	Chest Pain: A Relatively Benign Symptom of Type IV Hiatal Hernia. 2020 , 12, e11459	1
317	Efficacy and Safety of Robotic Dor Fundoplication on Severe Gastroesophageal Reflux Disease in Patients With Scleroderma. 2021 , 9, 23247096211051211	
316	A Case of Lansoprazole-Induced Bullous Pemphigoid After Zantac Recall. 2021 , 8, e00664	
315	Endoscopic and Surgical Management of Gastroesophageal Reflux Disease. 2021 , 50, 809-823	0
314	Endoscopic anti-reflux therapy for gastroesophageal reflux disease. 2021 , 27, 6601-6614	1
313	S1391 Reducing Inappropriate PPI Usage A QI Initiative at a Suburban Primary Care Clinic. <i>American Journal of Gastroenterology</i> , 2021 , 116, S638-S638	0.7
312	Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. 2021 ,	1
311	Esophageal Motility Disorders in the Natural History of Acid-Dependent Causes of Dysphagia and Their Influence on Patients' Quality of Life-A Prospective Cohort Study. 2021 , 18,	0
310	Osteopathic treatment in addition to standard care in patients with Gastroesophageal Reflux Disease (GERD) - A pragmatic randomized controlled trial.. 2022 , 29, 223-231	
309	Effectiveness of esophagogastroduodenoscopy in changing treatment outcome in refractory gastro-esophageal reflux disease. 2021 , 1-7	
308	How to Understand and Treat Laryngopharyngeal Reflux. 2021 , 50, 871-884	0
307	2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. 2021 , 27, 453-481	9
306	Risk of Enteric Infection in Patients with Gastric Acid Suppressive Drugs: A Population-Based Case-Control Study. 2021 , 11,	1
305	Functional Chest Pain and Esophageal Hypersensitivity: A Clinical Approach. 2021 , 50, 843-857	1
304	Gastritis, Esophagitis, and Peptic Ulcer Disease. 2014 , 1-9	
303	Primary Care Practitioners' Views on the Use of Proton Pump Inhibitors Associated with Alginate-Antacids for Better Gastroesophageal Reflux Disease Symptom Control: Results of a National Survey in Spain. 2014 , 04, 335-345	
302	Nonerosive Reflux Disease. 2015 , 88, 27	

301 Gastric Acid Secretions, Treatments, and Nutritional Consequences. **2015**, 553-595

300 Appendix C. Case Study Answer Keys. **2015**,

299 [Inadequate response to proton pump inhibitor therapy: causes and patient management tactics]. **2015**, 87, 85-89

298 GastroÖophageale Refluxerkrankung. **2015**, 1-11

297 Chapter 13: Heartburn and Dyspepsia. **2015**,

296 Chapter 25. Gastrointestinal Diseases. **2015**,

295 Benign Esophageal Disorders. **2015**, 175-218

294 Lifestyle Modifications in GERD. **2016**, 59-70

1

293 Nutritional Management of Upper Gastrointestinal Disorders. **2015**, 321-346

292 Barrett Esophagus and Esophageal Adenocarcinoma. 949-974

291 Surgical Management of GERD: Recommendations for Patient Selection and Preoperative Work-Up. **2016**, 19-29

290 How to Build the Trust of Your Referring Physicians. **2016**, 133-139

289 A study on parietal cell protrusion in patients taking long-term oral proton pump inhibitor. **2016**, 88, 42-45

288 Endolumenal GERD Therapies. **2016**, 189-215

287 Gastrointestinale Leitsymptome. **2016**, 2-31

286 His Upper GI Tract. **2016**, 51-67

285 Evaluation of the Influence of Hyoscine Butylbromide on the Oral Bioavailability of Lansoprazole in Healthy Adult Volunteers. **2016**, 07, 264-271

284 Sensitivity and specificity of the Gastrointestinal Short Form Questionnaire in diagnosis of gastroesophageal reflux disease. **2016**, 108, 174-80

3

- 283 Busted, Plausible or Confirmed. **2016**, 21,
- 282 Extraesophageal Manifestations of Gastroesophageal Reflux Disease. **2016**, 91, 257-263 4
- 281 Gastroesophageal Reflux and Bariatric Surgery. **2017**, 99-106
- 280 Medical Management of GERD: Algorithms and Outcomes. **2017**, 19-23
- 279 The current state of the art in the treatment of erosive esophagitis. **2017**, 6, 26
- 278 The management of gastro-oesophageal reflux disease in the UK Armed Forces. **2017**, 103, 200-205
- 277 Gastroesophageal Reflux Disease: Case-Based Learning. **2017**,
- 276 Gastroesophageal Reflux Disease. **2017**,
- 275 Gastroesophageal Reflux Disease: Faculty Materials. **2017**,
- 274 The Treatment of Chronic Cough by Osteopathy: A Case Study of a Patient with Refractory Gastroesophageal Reflux Disease. **2017**, 6,
- 273 Gastroesophageal Reflux Disease in Morbid Obesity Patients. **2017**, 6, 19-23
- 272 Nutritional Management of Upper Gastrointestinal Disorders. **2017**, 321-346
- 271 14 Nutritional Management of Upper Gastrointestinal Disorders. **2017**, 321-346
- 270 Differences in the Insulin Resistance Levels Measured by HOMA-IR between Patients with Erosive and Non-Erosive Gastroesophageal Reflux Disease. **2017**, 32, 139-144 1
- 269 Gastroesophageal Reflux Disease and Dental Erosions - A Mini Review. **2017**, 7,
- 268 Extra-esophageal GERD: Myth or Reality?. **2018**, 139-156
- 267 Medical Treatment for GERD in Asia. **2018**, 85-96
- 266 Investigations and Treatment of PPI Refractory GERD. **2018**, 97-112

265 Chapter 25: Gastrointestinal Diseases. **2017**,

264 THE ROLE OF PEPSINOGENES AND SOME INTESTINAL HORMONES IN PATHOGENESIS OF GASTROESOPHAGEAL REFLUX DISEASE. **2018**, 1, 3-8

1

263 Hiatushernienoperation bei schwierigen pathologisch-anatomischen Situationen am Hiatus. **2018**, 447-452

262 Gastroesophageal Reflux and Esophageal Dysmotility in Patients Undergoing Evaluation for Lung Transplantation: Assessment, Evaluation, and Management. **2018**, 279-299

261 Treatment. **2018**, 91-100

260 Imaging Reflux. **2018**, 105-114

259 Dental erosion caused by a gastrointestinal disorder in a child from the Late Holocene of Northeastern Brazil.

258 STRESS AND GASTROESOPHAGEAL REFLUX DISEASE. **2018**, 52, 10-15

0

257 Council for International Organizations of Medical Sciences (CIOMS) Ethical Guidelines: advancements and unsolved topics in 2016 upgrade. **2018**, 18, e7208

1

256 Features of Endoscopic Changes in Gastroesophageal Reflux Disease in Patients with Type II Diabetes Mellitus. **2018**, 3, 166-170

255 Non-Invasive Diagnosis of Gastroesophageal Reflux Disease Using Gastrin- and Pepsinogen-Based Tests. **2018**, 72, 172-176

254 Current trends in the diagnosis and treatment of gastroesophageal reflux disease. **2018**, 64, 588-594

2

253 MODERN CONCEPTS OF HEARTBURN PATHOGENESIS. **2018**, 33, 22-29

252 Management of gastroesophageal reflux disease: Patient and physician communication challenges and shared decision making. **2018**, 6, 892-900

2

251 GASTROESOPHAGEAL REFLUX DISEASE AND HELICOBACTER BACTERIAL INFECTION IN PATIENTS WITH CHRONIC HEPATITIS C WITH DIFFERENT TROPHOLOGICAL STATUS. **2019**, 4, 85

250 Gastroesophageal reflux disease questionnaire score and endoscopic findings in patients with gastroesophageal reflux disease. **2019**, 18, 63

0

249 Endoscopic Interventions. **2019**, 5-23

248 Medical Management of LPR. **2019**, 59-73

- 247 Gastroesophageal Reflux Disease. **2019**, 35-57
- 246 Endoscopic Management of Gastroesophageal Reflux Disease. **2019**, 253-261 1
- 245 Functional Swallowing Disorders. **2019**, 19-34
- 244 Gastro-esophageal Reflux Disease. **2019**, 133-142
- 243 Nasopharyngeal reflux. What do we know today?. **2019**, 27, 209 1
- 242 Performances of Diagnostic Methods in Gastroesophageal Reflux Disease. **2019**, 16, 41-50 1
- 241 Contemporary Approaches to the Treatment of Gastroesophageal Reflux Disease. **2019**, 29, 7-16 1
- 240 The prevalence of gastroesophageal reflux disease in an adult, South African black population, and the association with obesity. **2019**, 65, 100-106 1
- 239 Magnetic sphincter augmentation: Optimal patient selection and referral care pathways. **2019**, 11, 472-476 2
- 238 Evaluation and Management of Patients with Gastroesophageal Reflux Disease (GERD): TIF/Plication Methods. **2020**, 487-499
- 237 Gastroesophageal Reflux Disease. **2020**, 63-80
- 236 Comorbid patient with GERD and cardiovascular disease receiving antiplatelet therapy. The possibilities of choosing a proton pump inhibitor on a case study. **2019**, 10-16
- 235 Pathomorphological Aspects of Gastroesophageal Reflux Disease Diagnostics in Condition of Comorbidity with Hypothyroidism. **2019**, 4, 194-198
- 234 Basic Principles of Ambulatory pH Monitoring and Impedance. **2020**, 137-160 1
- 233 Radiofrequency Ablation (RFA) and Anti-Reflux MucoSectomy (ARMS) for Gastroesophageal Reflux Disease. **2020**, 339-344
- 232 Medical Treatment of GERD. **2020**, 121-143
- 231 Surgery in the Morbidly Obese Patient with Gastroesophageal Reflux Disease (GERD). **2020**, 165-171
- 230 Characteristics Of Motor-Secretory Disorders In Patients With Ischemic Heart Disease With Concomitant Gastroesophageal Reflux Disease. **2019**, 2019, 72-75

- 229 Clinical Efficacy and Safety of Yukgunja-tang for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. **2019**, 40, 16-28 0
- 228 Diagnostic Approach to Laryngopharyngeal Reflux. **2020**, 109-118
- 227 Gastrointestinal Complications. **2020**, 321-334
- 226 Gastritis, Esophagitis and Peptic Ulcer Disease. **2020**, 1-10
- 225 Gastro-esophageal reflux disease: limits of medical treatment and surgical indications. **2021**, 113, 356-363
- 224 Proton Pompa İnhibitorinin Uzun Dnem Kullanıadaki Etkileri.
- 223 Ultrasonographic measurement of the thickness of cervical oesophagus layers in the reflux oesophagitis: Association with clinical findings. **2020**, 7, 55-60
- 222 Bolus Detection in the Proximal Esophagus Using Pulse-Echo Ultrasound: A Feasibility Study. **2020**, 163, 569-571
- 221 Features of the Expression of Second-Type Melatonin Receptors by Esophagus Epiteliocytes in Gastroesophageal Reflux Disease. **2020**, 30, 26-34
- 220 Current management of proton pump inhibitor-refractory gastroesophageal reflux disease. **2020**, 5, 93-100
- 219 Refractory Gastroesophageal Reflux Disease: A Management Update. **2021**, 8, 765061 5
- 218 Upper Gastrointestinal Functional and Motility Disorders in Children. **2021**, 68, 1237-1253 3
- 217 Vorsorgegastroskopie lohnt sich das wirklich?. **2020**, 127-140
- 216 Impact of pharmacy-supported interventions on proportion of patients receiving non-indicated acid suppressive therapy upon discharge: A systematic review and meta-analysis. **2020**, 15, e0243134 2
- 215 A patient with heartburn practicing self-treatment, on an outpatient visit. **2020**, 28, 514-524
- 214 A retrospective study on the evaluation of the symptoms, medications and improvement of the quality of life of patients undergoing robotic surgery for gastroesophageal reflux disease. **2021**, 21, 174 0
- 213 Chest pain and palpitations in postmenopausal women with mitral valve prolapse, is there a gastroesophageal origin?. **2020**,
- 212 BRAZILIAN PHYSICIANS' PRACTICES ON THE MANAGEMENT OF SYMPTOMS SUGGESTING GASTROESOPHAGEAL REFLUX DISEASE: A MULTIDISCIPLINARY SURVEY. **2020**, 57, 404-408

- 211 Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. **2020**, 49, 2264-2274
- 210 Is Roux-en-Y Gastric Bypass Less Safe Than Sleeve Gastrectomy?. **2021**, 213-230
- 209 The indications for biopsy in routine upper gastrointestinal endoscopy. **2021**, 78, 215-227 2
- 208 Non-Barrett Esophagitis. **2021**, 33-53
- 207 Gastroesophageal reflux and asthma: when, how, and why. **2021**, 21, 52-58 2
- 206 The study and comparative analysis of GerdQ and GSRS Questionnaires on gastroesophageal reflux disease diagnostics. **2020**, 15, 323-329 4
- 205 Erosive and Nonerosive Esophagitis. **2020**, 195-200
- 204 Erkrankungen des Ösophagus. **2020**, 88-112
- 203 Surgical strategy for gastroesophageal reflux disease in patients with obesity. **2020**, 28, 43-49 1
- 202 PECULIARITIES OF STATE OF PROTECTION AND AGGRESSION FACTORS IN PATIENTS WITH DIABETES MELLITUS TYPE II AND GASTROESOPHAGEAL REFLUX DISEASE. **2020**, 1, 27-34 1
- 201 Esophageal Ulcers. **2020**, 400-403
- 200 The characteristics of antireflux surgery compared to proton pump inhibitor treatment in Korea: a nationwide study using claim data from 2007 to 2016. **2020**, 98, 254-261 1
- 199 Awareness, experience, and practice of physicians regarding adult gastroesophageal reflux disease (GERD) in Riyadh, Saudi Arabia. **2020**, 9, 4181-4189 0
- 198 Gastroesophageal reflux (Clinical case). **2020**, 17, 1-4
- 197 Association of gastro-oesophageal reflux disease and quality of life in patients with chronic rhinosinusitis. **2021**, 41, 450-460
- 196 Deprescribing Inappropriate Proton Pump Inhibitors in a Family Medicine Residency Practice Office. **2021**, 5, 43
- 195 Five-year outcomes for laparoscopic sleeve gastrectomy from a single center in Turkey. **2020**, 40, 310-315
- 194 Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study. **2020**, 35, 1084-1093 2

193	Efficacy of DA-5204 (Stillen 2X) for patients with gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled pilot study. 2020 , 99, e22729	1
192	Radiology of Benign Gastroesophageal Reflux Disease (GERD). 2021 , 71-82	
191	Anti-Reflux Surgery I: Funduplications. 2021 , 99-112	
190	Gastroenterology in the Aging Male. 2021 , 185-204	1
189	Pantoprazole niche among the GERD-medicines. 2020 , 47-53	
188	Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study.	
187	Chapter 13: Heartburn and Dyspepsia. 2020 ,	
186	Focus on gastroesophageal reflux disease in patients with cystic fibrosis. 2020 , 26, 6322-6334	3
185	Initiatives to reduce the inappropriate use of proton pump inhibitors in an outpatient primary care clinic. 2020 , 78, 497-498	
184	Mind the Gap: Current Treatment Alternatives for GERD Patients Failing Medical Treatment and Not Ready for a Fundoplication. 2020 , 31, 264-276	2
183	Advances in the diagnosis of GERD. 2021 , 59, 3-9	0
182	Highlights From the New ACG Guidelines for the Diagnosis and Management of GERD. 2013 , 9, 377-9	1
181	Reflux esophagitis in war-related sulfur mustard lung disease. 2014 , 28, 30	1
180	Effect of a Combination of Omeprazole Plus Sustained Release Baclofen Versus Omeprazole Alone on Symptoms of Patients with Gastroesophageal Reflux Disease (GERD). 2014 , 13, 1221-6	10
179	The importance of the mesh shape in preventing recurrence after Nissen fundoplication. 2015 , 8, 9684-91	1
178	Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy. 2014 , 10, 547-55	7
177	Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. 2017 , 63, 354-364	142
176	The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders. 2018 , 14, 169-175	3

175	Barrett's Esophagus. 2018 , 115, 211-213		5
174	Gastroesophageal Reflux Disease (GERD). 2018 , 115, 214-218		15
173	Laryngopharyngeal Reflux and Functional Laryngeal Disorder: Perspective and Common Practice of the General Gastroenterologist. 2018 , 14, 512-520		3
172	Influence of working in auto factory on gastroesophageal reflux disease. 2018 , 11, S1-S7		2
171	Review of the Long-Term Effects of Proton Pump Inhibitors. 2017 , 34, 19-23		
170	Treatment of Refractory Gastroesophageal Reflux Disease. 2020 , 16, 196-205		2
169	EZH2-mediated suppression of CLDN1 leads to barrier dysfunction in PPI-refractory gastroesophageal reflux disease. 2021 ,		1
168	Degree of concordance on the management of patients with gastroesophageal reflux disease. A study among specialists that are members of the Sociedad Latinoamericana de Neurogastroenterología (SLNG). 2021 ,		
167	Esophageal Pressure and Clinical Assessments in the Gastroesophageal Reflux Disease Patients with Laryngopharyngeal Reflux Disease. 2021 , 10,		
166	Heartburn Center Set-Up in a Community Setting: Engineering and Execution. 2021 , 8, 662007		
165	ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2021 ,	0.7	34
164	Advanced Endoscopic Imaging and Interventions in GERD: An Update and Future Directions.. 2021 , 8, 728696		1
163	Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects. 2021 , 12, 754849		0
162	A Retrospective Study of the Safety and Efficacy of Endoscopic Radiofrequency Therapy Under Direct Vision in 59 Patients with Gastroesophageal Reflux Disease from 2 Centers in Beijing, China Using the Gastroesophageal Reflux Disease Questionnaire.. 2022 , 28, e933848		
161	Cross-Functional Syndrome of Gastrointestinal Diseases in Adults and Children in the Context of Their Continuity. 2021 , 76, 458-464		0
160	Beyond the Eckardt Score: Patient-Reported Outcomes Measures in Esophageal Disorders. 2021 , 23, 29		0
159	Effects of acids, pepsin, bile acids, and trypsin on laryngopharyngeal reflux diseases: physiopathology and therapeutic targets. 2021 , 1		4
158	On-demand Versus Continuous Maintenance Treatment of Gastroesophageal Reflux Disease With Proton Pump Inhibitors: A Systematic Review and Meta-analysis.. 2022 , 28, 5-14		0

157 GastroÖophageale Refluxerkrankung. **2015**, 1-11

156 GASTROESOPHAGEAL REFLUX DISEASE: A PRACTICAL APPROACH.. **2021**, 58, 525-533

155 Analysis of Psychological and Gut Microbiome Characteristics in Patients With Non-erosive Reflux Disease.. **2021**, 12, 741049

154 Effects of Obesity Surgery on GERD and Esophageal Motility. 263451612110691

153 Gastritis, Esophagitis, and Peptic Ulcer Disease. **2022**, 1227-1236

152 Gastroesophageal Reflux Disease: Diagnosis and Management Approach, Literature Review. **2022**, 11, 1-3

151 Recommendations for endoscopic surveillance after esophageal atresia repair in adults.. **2022**,

150 Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial.. **2022**, 1

149 Features of therapeutic correction of GERD: focus on cytoprotection (with a clinical case). **2022**, 87-92

148 Thailand Guideline 2020 for Medical Management of Gastroesophageal Reflux Disease (GERD).. **2021**,

147 Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.. **2022**,

146 The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study.. **2022**, 13, 791074

145 Does omeprazole, the proton-pump inhibitor, affects the structure of the kidney of male albino rats? histological and laboratory study. **2022**,

144 Association of CYP2C19 polymorphism with proton pump inhibitors effectiveness and with fractures in real-life: retrospective cohort study.. **2022**,

143 Nutrition management in adults with cystic fibrosis.. **2022**,

142 The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children. **2021**,

141 Update on Management of Squamous Cell Esophageal Cancer.. **2022**, 24, 375

140 The Effect of the Preoperative Fasting Regimen on the Incidence of Gastro-Oesophageal Reflux in 90 Dogs.. **2021**, 12,

139	Multicenter study of gastroesophageal reflux disease symptoms prevalence in outpatients in Russia. 2022 , 94, 48-56	1
138	Benign Gastrointestinal Conditions. 2022 , 297-330	
137	Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience.. 2022 , 13, 21501319221088688	1
136	Laparoscopic Nissen Fundoplication for GERD: Current Perspective. 2022 , 1-32	
135	Risk factors and long-term course of gastroesophageal reflux disease after peroral endoscopic myotomy: A large-scale multicenter cohort study in Japan.. 2022 ,	1
134	The views of African and Middle Eastern Gastroenterologists on the management of mild-to-moderate, non-erosive gastro-esophageal reflux disease (GERD).. 2022 ,	0
133	Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.. 2022 , 57, 267	4
132	Gastroesophageal reflux disease. 2022 , 815-838	
131	Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn.. 2022 ,	3
130	Utilization of the Caprini Score for Risk Stratification of the Arthroplasty Patient in the Prevention of Postoperative Venous Thrombosis.. 2022 ,	1
129	Impact of COVID-19 pandemic on pediatric endoscopy: A multicenter study on behalf of the SIGENP Endoscopy Working Group.. 2022 ,	1
128	In Vitro Investigation of Potential Pepsin Inhibitors: New Perspectives for the Treatment of Gastroesophageal Reflux. 2022 , 18,	
127	The effects of diaphragmatic breathing training on the quality of life and clinical symptoms of patients with gastroesophageal reflux disease: A randomized controlled trial. 2022 ,	
126	2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022 , 97, 70-92	
125	Epidemiological and clinical risk factors for non-erosive reflux disease, erosive esophagitis and Barrett's esophagus in Russia. 2021 , 12, 176-180	
124	The relationship between gastroesophageal reflux disease and recurrent wheezing in children.. 2021 , 100, e27660	0
123	Combined Curcumin and Lansoprazole-Loaded Bioactive Solid Self-Nanoemulsifying Drug Delivery Systems (Bio-SSNEDDS).. 2021 , 14,	2
122	Variability in endoscopic assessment of Nissen fundoplication wrap integrity and hiatus herniation.. 2021 ,	2

- 121 Endoscopic Findings of Gastro-Esophageal Reflux Disease in Elderly and Younger Age Groups.. **2021**, 8, 606205 2
- 120 Assessment of esophagogastric junction morphology by dynamic real-time MRI: comparison of imaging features to high-resolution manometry. **2021**, 40, 376
- 119 Chronic Omeprazole use in the elderly is associated with decreased risk of dementia and cognitive decline.. **2021**, 0
- 118 Prevalence of Gastroesophageal Disease and Associated Risk Factors Among the Population in Al-Qunfudah.. **2021**, 13, e20325
- 117 Itopride in treatment of laryngopharyngeal symptoms of gastroesophageal reflux disease.. **2021**, 75, 38-44
- 116 Inter-specialty collaboration in the formalization of a new foregut subspecialty.. **2021**, 16, e0262019
- 115 Restoration for the foregut surgery: bridging gaps between foregut surgery practice and academia. **2021**, 24, 175-179 0
- 114 Gastro-oesofageale reflux bij kinderen van 0-18 maanden. **2022**, 621-630
- 113 Chapter 25: Gastrointestinal Diseases. **2022**,
- 112 Factors that Impact Day-to-Day Esophageal Acid Reflux Variability and Its Diagnostic Significance for Gastroesophageal Reflux Disease.. **2022**, 1 0
- 111 Efficacy of Endoscopic and Surgical Treatments for Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-Analysis.. **2022**, 12, 1
- 110 Endoscopic tightening of the cardia mucosa in gastroesophageal reflux disease: A case series of 120 patients up to 1-year follow-up.. **2022**, 8, 138-142
- 109 The Effect of Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Meals on Transient Lower Esophageal Relaxations (TLESR) in Gastroesophageal Reflux Disease (GERD) Patients with Overlapping Irritable Bowel Syndrome (IBS).. **2022**, 14, 0
- 108 Enfermedades del esófago (I): enfermedad por reflujo gastroesofágico. Diagnóstico y tratamiento. **2022**, 29, 164-173
- 107 Narrow Band Imaging for Diagnosis of Non-Erosive Reflux Disease: An International, Multicenter, Randomized Controlled Trial.. **2022**, 1
- 106 Gastroesophageal Reflux Disease and Asthma: A Narrative Review. **2022**, 1
- 105 WAO-ARIA consensus on chronic cough [Part III: Management strategies in primary and cough-specialty care. Updates in COVID-19. **2022**, 15, 100649 0
- 104 Current advances in the diagnosis and management of gastroesophageal reflux disease. **2022**, 1

- 103 Gastroesophageal reflux disease: risk factors, current possibilities of diagnosis and treatment optimisation. **2022**, 16-26 2
- 102 Lean/normal-weight Metabolic Dysfunction-Associated Fatty Liver Disease is a Risk Factor for Reflux Esophagitis.. **2022**, 1
- 101 Association between gastroesophageal reflux disease and coronary atherosclerosis.. **2022**, 17, e0267053
- 100 Endoscopic tightening of the cardia mucosa in gastroesophageal reflux disease: A case series of 120 patients up to 1-year follow-up.. **2022**, 8, 147-151
- 99 CHANGES IN SERUM GHRELIN AND ITS RELATIONSHIP WITH OF BODY MASS INDEX IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE AND SPONDYLOARTHRITIS. **2022**, 75, 982-986
- 98 Gastroesophageal Reflux Disease. **2022**, 39-53
- 97 Age-related features of gastritis activity in schoolchildren with gastroesophageal reflux disease. **2022**, 25, 116-120 0
- 96 Comparison in Adherence to Treatment between Patients with Mild/Moderate and Severe Reflux Esophagitis: A Prospective Study. **2022**, 11, 3196 0
- 95 Gastrointestinal Features of 22Q11.2 Deletion Syndrome Include Chronic Motility Problems from Childhood to Adulthood. Publish Ahead of Print, 0
- 94 Population pharmacokinetics of esomeprazole in patients with preterm preeclampsia.
- 93 Recent Advances in the Endoscopic Management of Gastro-esophageal Reflux Disorder: A Review of Literature. **2022**, 0
- 92 Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation.
- 91 Chronic cough in adults: recommendations from an Italian intersociety consensus.
- 90 The Use of Elimination Diets in Gastrointestinal Disease: a Review.
- 89 Atrophic gastritis is inversely associated with gastroesophageal reflux disease in a twin register based study.
- 88 Predictors for inappropriate proton pump inhibitor use: observational study in primary care. BJGP.2022.0178
- 87 Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan. **2022**, 17, e0270252
- 86 Distal esophageal wall thickness correlates with dysphagia in adult patients with eosinophilic esophagitis. 1

85	The Effects of Modifying Amount and Type of Dietary Carbohydrates on Esophageal Acid Exposure Time and Esophageal Reflux Symptoms: A Randomized Controlled Trial.. <i>American Journal of Gastroenterology</i> , 2022 , Publish Ahead of Print,	0.7	0
84	Nonsurgical management of GERD in obesity. 2022 , 77-90		
83	Clinical use of mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index for the diagnosis of gastro-esophageal reflux disease.		0
82	Transoral incisionless fundoplication is cost-effective for treatment of gastroesophageal reflux disease. 2022 , 10, E923-E932		0
81	Medical conditions associated with coffee consumption: Disease-trajectory and comorbidity network analyses of a prospective cohort study in UK Biobank.		2
80	Evaluation of Methods of Gastroesophageal Reflux Disease Diagnosis in Thawra Teaching Hospital Elbaida Libya. 2018 , 33, 290-297		
79	Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. 2022 , 9, e000941		
78	Evaluation of proton pump inhibitor administration in hospitalized dogs in a tertiary referral hospital.		
77	Medicinal Plants for Gastrointestinal Diseases. 2022 , 124-140		
76	Adapting Simon's Two-Stage Design for Efficient Screening of Filovirus Vaccines in Non-Human Primates. 2022 , 10, 1216		
75	Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.		
74	Effect of laparoscopic angle of His reconstruction in the treatment of patients with gastroesophageal reflux disease and hiatal hernia. Publish Ahead of Print,		
73	Differences between early and late-onset asthma: role of comorbidities on symptom control. 2022 ,		1
72	Neuropsychological assessment after long-term omeprazole treatment. 1-9		
71	Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis.		0
70	Relationship between gastroesophageal reflux disease and objective sleep quality.		0
69	Review of Gastroesophageal Reflux Pharmacotherapy Management.		
68	Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?. 2022 , 15, 1033		1

- 67 The Lyon Consensus Criteria for GERD Diagnosis in a Greek Population: The Clinical Impact and Changes in GERD Diagnosis in a Real-World, Retrospective Study. **2022**, 11, 5383 ○
- 66 Foregut surgery in Jordan. 3, ○
- 65 Proton pump inhibitor deprescription: A rapid review. 58, ○
- 64 Viszeralchirurgie. **2022**, 223-437 ○
- 63 Dysphagia During Pregnancy and the Postpartum Period. **2022**, 241-250 ○
- 62 Gastroenterological manifestations associated with 22q11.2 deletion syndrome. **2022**, 182-209 ○
- 61 The role of vonoprazan in patients with erosive esophagitis. **2022**, 15, 175628482211226 ○
- 60 Endoscopic Treatment of Reflux. Publish Ahead of Print, ○
- 59 An expert opinion on antacids: A review of its pharmacological properties and therapeutic efficacy. 11, 1057 ○
- 58 Overlap syndrome: association of gastroesophageal reflux disease with dyspepsia syndrome in schoolchildren. **2022**, 67, 54-59 ○
- 57 Gastroesophageal Reflux Disease Increases Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease. **2022**, ○
- 56 Gastro-oesophageal reflux disease in children with neurological impairment: a retrospective cohort study. **2022**, 6, e001577 ○
- 55 Dietary weight loss intervention provides improvement of gastroesophageal reflux disease symptoms: A randomized clinical trial. ○
- 54 Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis. ○
- 53 Prevalence, Predictors, and Management of Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy: a Multicenter Cohort Study. ○
- 52 Repairing small type I hiatal hernias at the time of RYGB is not necessary to achieve resolution of reflux symptoms. ○
- 51 Diagnostic thresholds and optimal collection protocol of salivary pepsin for gastroesophageal reflux disease. ○
- 50 Factors Associated with Increased Severity of Erosive Esophagitis 1 Year After Laparoscopic Sleeve Gastrectomy. ○

- 49 Approach to Etiological Diagnosis and Initial Management. **2022**, 117-151 ○
- 48 Noncardiac Esophageal Chest Pain -A Comprehensive Review. **2022**, 19, 23-31 ○
- 47 A Comparative Study on Mono-therapy and Combination Therapy of Additive Drugs (Rebamipide and Pantoprazole) with Amla and Honey combination for the Treatment of Gastroesophageal Reflux Disease and Intestinal motility. **2022**, 4144-4150 ○
- 46 Can the marshmallow esophagram replace high-resolution manometry as an appropriate screening for esophageal motility prior to anti-reflux surgery?. **2022**, ○
- 45 Concise Review: Applicability of High-resolution Manometry in Gastroesophageal Reflux Disease. **2022**, 28, 531-539 ○
- 44 Clinical efficacy and mechanism of transcutaneous neuromodulation on ineffective esophageal motility in patients with gastroesophageal reflux disease. ○
- 43 Necessity of pathological examination of reflux esophagitis. ○
- 42 Esophageal Function Tests. **2022**, 31-39 ○
- 41 Holistic management of symptomatic reflux: rising to the challenge of proton pump inhibitor overuse. **2022**, 72, 541-544 ○
- 40 Using an algorithm to assess the rate and trend over time of inappropriate proton pump inhibitors prescription upon hospital discharge. **2022**, ○
- 39 Laryngopharyngeal Reflux Disease and Gastroesophageal Reflux Disease Can Mutually Influence. **2022**, ○
- 38 CHANGES IN PROSTAGLANDIN LEVELS IN BLOOD SERUM OF PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE ON THE BACKGROUND OF THE OSTEOCHONDROSIS OF THE SPINE AND OBESITY. **2022**, 75, 2497-2500 ○
- 37 Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications. **2022**, ○
- 36 Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. 28, 6294-6309 ○
- 35 Investigation of the potential relationship between gastroesophageal reflux disease and laryngopharyngeal reflux disease in symptomatology [a prospective study based on a multidisciplinary outpatient. 1-7 ○
- 34 Relationship Between COPD and GERD: A Bibliometrics Analysis. Volume 17, 3045-3059 ○
- 33 Feasibility and Efficacy of Magnetic Sphincter Augmentation for the Management of Gastroesophageal Reflux Disease Post-Sleeve Gastrectomy for Obesity. ○
- 32 Community pharmacists' response to complaints of gastroesophageal reflux: A simulated patient study in the Northern United Arab Emirates. **2023**, 18, e0279922 ○

- 31 Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden. ○
- 30 Clinical Manifestations and Surgical Indications of Gastroesophageal Reflux Disease. **2023**, 15-21 ○
- 29 Anti-reflux Surgery to Extra-esophageal Manifestations of GERD. **2023**, 23-29 ○
- 28 Various Techniques of Anti-reflux Treatment. **2023**, 51-62 ○
- 27 Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers. **2023**, 13, ○
- 26 Efficacy of laparoscopic Toupet fundoplication compared to endoscopic and surgical procedures for GERD treatment: a randomized trials network meta-analysis. **2023**, 408, ○
- 25 Endoluminal Gastroesophageal Reflux Disease Therapies. **2023**, 347-376 ○
- 24 Assessing the genetic relationship between gastroesophageal reflux disease and chronic respiratory diseases: A Mendelian randomization study. ○
- 23 Sex Differences in GERD. 263451612311661 ○
- 22 Pediatric Neurogastroenterology and Motility Disorders. **2023**, 33, 379-399 ○
- 21 Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. ○
- 20 Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers. **2023**, 24, 2378 ○
- 19 Management of gastro-esophageal reflux disease: Practice-oriented answers to clinical questions. 29, 773-779 ○
- 18 Updated the Maastricht VI/Florence Consensus recommendations for the treatment of <i>Helicobacter pylori</i> infection: A review. **2023**, 24, 851-859 ○
- 17 Baclofen as a therapeutic option for gastroesophageal reflux disease: A systematic review of clinical trials. 10, ○
- 16 Dietary approaches to stop hypertension (DASH)-style diet in association with gastroesophageal reflux disease in adolescents. **2023**, 23, ○
- 15 Symptoms, the GerdQ score and patients characteristics do not predict gastroesophageal reflux disease in patients with proton-pump-inhibitor-refractory reflux symptoms Results from a large prospective database. 11, e14802 ○
- 14 Comparing Gerd and Non-GERD Patients Regarding Knowledge Level of Acute Myocardial Infarction Symptoms, Risk Factors and Immediate Action Must Be Taken in Eastern Province, Saudi Arabia. **2023**, ○

- 13 Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. **2023**, 14, 204209862311540 ○
- 12 The long-term efficacy of transoral incisionless fundoplication with Medigus Ultrasonic Surgical Endostapler (MUSE) for gastroesophageal reflux disease. ○
- 11 Effects of Helicobacter pylori eradication on esophageal motility, esophageal acid exposure, and gastroesophageal reflux disease symptoms. 13, ○
- 10 Chinese consensus on multidisciplinary diagnosis and treatment of gastroesophageal reflux disease 2022. **2023**, ○
- 9 BTS Clinical Statement on the prevention and management of community-acquired pneumonia in people with learning disability. **2023**, 78, s22-s52 1
- 8 Haze, Gray, and Endoscopy Underway. **2023**, 315-367 ○
- 7 Severity and geographical disparities of post-COVID-19 symptoms among the Vietnamese general population: a national evaluation. **2023**, 13, ○
- 6 Impact of Ramadan Fasting on the Severity of Symptoms Among a Cohort of Patients With Gastroesophageal Reflux Disease (GERD). **2023**, ○
- 5 Prevalence of Non-erosive Esophageal Phenotypes in Children: A European Multicenter Study. **2023**, 29, 156-165 ○
- 4 CHANGES IN SERUM SOMATOSTATIN AND GASTRIN LEVELS IN PATIENTS AFTER CHOLECYSTECTOMY AND GASTROESOPHAGEAL REFLUX DISEASE. **2023**, 76, 548-553 ○
- 3 Medical Therapy for GERD. **2023**, 29-38 ○
- 2 Phenotypes of Gastroesophageal Reflux Disease and Personalized Management. **2023**, 39-48 ○
- 1 RefluxÖsophagitis: Kontrollen durch Ösophago-Gastro-Duodenoskopie. **2015**, 91, 387-389 ○